Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Malignant Lymphoma

  Free Subscription

Articles published in Leuk Lymphoma

Retrieve available abstracts of 373 articles:
HTML format

Single Articles

    June 2022
  1. STUVER R, Lewis NE, Ewalt MD, Dogan A, et al
    First report of bilateral breast-implant associated anaplastic large cell lymphoma caused by identical T-cell clone.
    Leuk Lymphoma. 2022 Jun 25:1-4. doi: 10.1080/10428194.2022.2092860.

  2. CHAHAL M, Hayden A, Savage KJ, Villa D, et al
    Outcomes after initial refusal of curative treatment in patients with classic Hodgkin lymphoma.
    Leuk Lymphoma. 2022 Jun 24:1-4. doi: 10.1080/10428194.2022.2087071.

  3. KOHN M, Alsuliman T, Lamure S, Cheminant M, et al
    Characteristics of SARS-CoV-2 infection in lymphoma/chronic lymphocytic leukemia patients during the Omicron outbreak.
    Leuk Lymphoma. 2022 Jun 18:1-5. doi: 10.1080/10428194.2022.2086249.

  4. SYMES E, Wang P, Lager AM, Bishop MR, et al
    TP53/PLCG2-mutated diffuse large B-cell lymphoma richter transformation (DLBCL-RT) of CLL with unusual CD2 and PD-1 expression.
    Leuk Lymphoma. 2022 Jun 18:1-4. doi: 10.1080/10428194.2022.2087070.

  5. QUALLS D, Kumar A, Epstein-Peterson ZD
    Targeting the immune microenvironment in mantle cell lymphoma: implications for current and emerging therapies.
    Leuk Lymphoma. 2022 Jun 15:1-13. doi: 10.1080/10428194.2022.2086244.
    PubMed     Abstract available

  6. ERIKSEN PRG, Clasen-Linde E, Brown PN, Haunstrup L, et al
    NK- and T-cell lymphoma of the nasal cavity and paranasal sinuses in Denmark 1980-2017: a nationwide cohort study.
    Leuk Lymphoma. 2022 Jun 14:1-10. doi: 10.1080/10428194.2022.2087069.
    PubMed     Abstract available

  7. LEVY M, Dupuis J, Charpy C, Martin A, et al
    Rituximab or rituximab plus chlorambucil for translocation (11;18)-negative gastric mucosa-associated lymphoid tissue lymphoma: a monocentric non-randomized observational study.
    Leuk Lymphoma. 2022 Jun 10:1-7. doi: 10.1080/10428194.2022.2086248.
    PubMed     Abstract available

  8. TEO YH, Teo YN, Khoo LP, Chang EWY, et al
    Clinicopathological factors affecting prognosis in marginal zone lymphoma in Asian patients: a cohort study.
    Leuk Lymphoma. 2022 Jun 10:1-4. doi: 10.1080/10428194.2022.2086242.

  9. SEITTER SJ, McClelland PH, Ahlman MA, Goff SL, et al
    Durable remissions in two adult patients with Burkitt lymphoma following anti-CD19 CAR T-cell therapy: a single center experience.
    Leuk Lymphoma. 2022 Jun 9:1-5. doi: 10.1080/10428194.2022.2076853.

  10. ALLEN PB, Goyal S, Switchenko J, Tarabadkar E, et al
    Mitigation strategies among cutaneous T-cell lymphoma patients with positive Staphylococcus aureus skin and soft tissue cultures have unclear impacts on the risk of subsequent bacteremia.
    Leuk Lymphoma. 2022 Jun 7:1-8. doi: 10.1080/10428194.2022.2081324.
    PubMed     Abstract available

  11. ARULOGUN SO, Abbasi MA, Pomplun S, O'Neill AT, et al
    Clinicoradiopathological correlation of symptomatic focal bone marrow lesions in Waldenstrom Macroglobulinaemia.
    Leuk Lymphoma. 2022;63:1496-1499.

  12. TAHIR F, Sy J, Reddel S, Trotman J, et al
    Progressive multifocal leukoencephalopathy post ibrutinib therapy in relapsed chronic lymphocytic leukaemia.
    Leuk Lymphoma. 2022;63:1464-1468.
    PubMed     Abstract available

  13. GE J, Xia Y, Sun Z, Zhang L, et al
    Improving outcomes in limited-stage de novo CD5+ DLBCL: systemic approaches with consolidative radiation.
    Leuk Lymphoma. 2022;63:1369-1374.
    PubMed     Abstract available

    May 2022
  14. BERGER T, Geiger KR, Yeshurun M, Gafter-Gvili A, et al
    Repeat biopsy in relapsed or refractory diffuse large B cell lymphoma: a nationwide survey and retrospective study.
    Leuk Lymphoma. 2022 May 28:1-8. doi: 10.1080/10428194.2022.2081325.
    PubMed     Abstract available

  15. TARIQ H
    Classic Hodgkin lymphoma cloaked in an intense sarcoid-like reaction.
    Leuk Lymphoma. 2022 May 27:1-4. doi: 10.1080/10428194.2022.2081848.

  16. MAN J, Wang H, Qian X, Chen L, et al
    TCF3 protein was highly expressed in pediatric Burkitt lymphoma and predicts poor prognosis: a single-center study.
    Leuk Lymphoma. 2022 May 26:1-8. doi: 10.1080/10428194.2022.2076852.
    PubMed     Abstract available

  17. STRUSSMANN T, Wasch R, Scherer F, Mutter JA, et al
    A patient with refractory high-grade B-cell lymphoma and rapid progression under CAR-T-cell therapy was successfully salvaged with inotuzumab- ozogamicin.
    Leuk Lymphoma. 2022 May 20:1-3. doi: 10.1080/10428194.2022.2074991.

  18. GORDON MJ, Sureda A, Westin JR
    Novel strategies for relapsed/refractory DLBCL; navigating the immunotherapy era in aggressive lymphoma.
    Leuk Lymphoma. 2022 May 12:1-11. doi: 10.1080/10428194.2022.2068007.
    PubMed     Abstract available

  19. LO AC, Holloway CL, Savage KJ, Sehn LH, et al
    Radioimmunotherapy for orbital marginal zone lymphoma: a retrospective review.
    Leuk Lymphoma. 2022 May 5:1-4. doi: 10.1080/10428194.2022.2060505.

  20. EVANS MG, Shestakova A, Haghighi N, Zhao X, et al
    Rare case of leptomeningeal small lymphocytic lymphoma with TP53 mutation detected by deep next-generation sequencing.
    Leuk Lymphoma. 2022 May 3:1-5. doi: 10.1080/10428194.2022.2070911.
    PubMed     Abstract available

  21. LEBEL E, Goldschmidt N, Siegal T, Lossos A, et al
    Rituximab, methotrexate, procarbazine and lomustine (R-MPL) for the treatment of primary Central nervous system lymphoma.
    Leuk Lymphoma. 2022 May 2:1-7. doi: 10.1080/10428194.2022.2064996.
    PubMed     Abstract available

    April 2022
  22. PHAM TM, Quy PN, Amin K, Walker E, et al
    Average lifespan shortened due to Hodgkin lymphoma, non-Hodgkin lymphoma, multiple myeloma, and leukemia in Japan, 1990-2015.
    Leuk Lymphoma. 2022 Apr 23:1-10. doi: 10.1080/10428194.2022.2064990.
    PubMed     Abstract available

  23. PUCKRIN R, Chua N, Shafey M, Stewart DA, et al
    Improving the outcomes of secondary CNS lymphoma with high-dose thiotepa, busulfan, melphalan, rituximab conditioning and autotransplant.
    Leuk Lymphoma. 2022 Apr 22:1-9. doi: 10.1080/10428194.2022.2068005.
    PubMed     Abstract available

  24. JUUL MB, Jelicic J, Anru PL, Engberg H, et al
    Cardiovascular diseases in elderly survivors of diffuse large B-cell lymphoma: a Danish population-based cohort study.
    Leuk Lymphoma. 2022 Apr 18:1-10. doi: 10.1080/10428194.2022.2064982.
    PubMed     Abstract available

  25. MAZIARZ RT, Yang H, Liu Q, Wang T, et al
    Real-world healthcare resource utilization and costs associated with tisagenlecleucel and axicabtagene ciloleucel among patients with diffuse large B-cell lymphoma: an analysis of hospital data in the United States.
    Leuk Lymphoma. 2022 Apr 14:1-11. doi: 10.1080/10428194.2022.2060503.
    PubMed     Abstract available

  26. SCHUSTER SJ, Zhang J, Yang H, Agarwal A, et al
    Comparative efficacy of tisagenlecleucel and lisocabtagene maraleucel among adults with relapsed/refractory large B-cell lymphomas: an indirect treatment comparison.
    Leuk Lymphoma. 2022;63:845-854.
    PubMed     Abstract available

  27. DOI Y, Yokota T, Shibayama H, Matsumoto K, et al
    A forodesine-based regimen as a therapeutic option for PTCL-NOS with Central nervous system involvement.
    Leuk Lymphoma. 2022;63:1013-1015.

    March 2022
  28. LO AC, Major A, Super L, Appel B, et al
    Practice patterns for the management of nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL): an international survey by the Global NLPHL One Working Group (GLOW).
    Leuk Lymphoma. 2022 Mar 31:1-4. doi: 10.1080/10428194.2022.2053533.

  29. LIU L, Adlowitz DG, Rock P, Casulo C, et al
    Hypergammaglobulinemia as a presenting feature of Mantle cell lymphoma.
    Leuk Lymphoma. 2022 Mar 31:1-4. doi: 10.1080/10428194.2022.2056177.

  30. WANG W, Mai B, Ali H, Chen L, et al
    Uncommon histiocyte-rich pseudotumor after chemotherapy in peripheral T-cell lymphoma.
    Leuk Lymphoma. 2022 Mar 31:1-3. doi: 10.1080/10428194.2022.2056176.

  31. RIBERA JM, Garcia O, Buendia-Urena B, Terol MJ, et al
    Validation of the Burkitt Lymphoma International Prognostic Index in patients treated with two prospective chemoimmunotherapy trials in Spain.
    Leuk Lymphoma. 2022 Mar 27:1-4. doi: 10.1080/10428194.2022.2053531.

  32. ZHOU J, Huang J, Xiao M, Wang Y, et al
    Epstein-Barr virus copy number in peripheral blood mononuclear cells predicts prognosis in diffuse large B cell lymphoma.
    Leuk Lymphoma. 2022 Mar 11:1-9. doi: 10.1080/10428194.2022.2045595.
    PubMed     Abstract available

  33. BEN BAROUCH S, Bhella S, Kridel R, Kukreti V, et al
    Long-term follow up of relapsed/refractory non-Hodgkin lymphoma patients treated with single-agent selinexor - a retrospective, single center study.
    Leuk Lymphoma. 2022 Mar 9:1-8. doi: 10.1080/10428194.2022.2047674.
    PubMed     Abstract available

  34. KIM MS, Banerjee T, Chen A, Danilov A, et al
    A phase II study of obinutuzumab in combination with ibrutinib for treatment of relapsed mantle cell lymphoma.
    Leuk Lymphoma. 2022 Mar 9:1-3. doi: 10.1080/10428194.2022.2045598.

    The ABVD's of cooperative trials in pediatric Hodgkin lymphoma: The India experience.
    Leuk Lymphoma. 2022 Mar 6:1-3. doi: 10.1080/10428194.2022.2045602.

  36. MOORE DC, Elmes JB, Strassels SA, Patel JN, et al
    Brentuximab vedotin-induced pancreatitis in lymphoma: a pharmacovigilance study.
    Leuk Lymphoma. 2022 Mar 6:1-2. doi: 10.1080/10428194.2022.2045601.

  37. FITZGERALD KN, Quesada AE, von Keudell G, Raj S, et al
    CD19 epitope masking by tafasitamab leads to delays in subsequent use of CD19 CAR T-cell therapy in two patients with aggressive mature B-cell lymphomas.
    Leuk Lymphoma. 2022;63:751-754.

    February 2022
  38. SIDDIQI T, Coutre S, McKinney M, Barr PM, et al
    Characterization of low-grade arthralgia, myalgia, and musculoskeletal pain with ibrutinib therapy: pooled analysis of clinical trials in patients with chronic lymphocytic leukemia and mantle cell lymphoma.
    Leuk Lymphoma. 2022 Feb 28:1-9. doi: 10.1080/10428194.2022.2038372.
    PubMed     Abstract available

  39. WANG WJ, Omo-Ogboi AC, Rivera Rivera X, Moosvi AM, et al
    Bone primary, spindle cell variant of diffuse large B-cell lymphoma presenting in the femur from a Paget's disease patient.
    Leuk Lymphoma. 2022 Feb 27:1-3. doi: 10.1080/10428194.2022.2043305.

  40. MEHTA-SHAH N, Bartlett NL, Kahl B, Watkins MP, et al
    COVID-19 booster vaccines generate seroconversion in subset of patients with lymphoma/CLL: single institution experience.
    Leuk Lymphoma. 2022 Feb 27:1-5. doi: 10.1080/10428194.2022.2038377.

  41. MUKHERJEE A, Milton DR, Jabbour EJ, Gulbis AM, et al
    Clinical outcome of allogeneic stem cell transplantation in patients with B-cell lymphoid malignancies following treatment with targeted small molecule inhibitors.
    Leuk Lymphoma. 2022 Feb 27:1-9. doi: 10.1080/10428194.2022.2043302.
    PubMed     Abstract available

  42. BARR PM, Smith S, Roschewski M, O'Brien SM, et al
    Phase 1/2 study of acalabrutinib and the PI3K delta inhibitor ACP-319 in relapsed/refractory B-cell Non-Hodgkin lymphoma.
    Leuk Lymphoma. 2022 Feb 24:1-5. doi: 10.1080/10428194.2022.2043301.

  43. TAN JY, Qiu TY, Chiang J, Tan YH, et al
    Burkitt lymphoma - no impact of HIV status on outcomes with rituximab-based chemoimmunotherapy.
    Leuk Lymphoma. 2022 Feb 19:1-11. doi: 10.1080/10428194.2022.2027402.
    PubMed     Abstract available

  44. KARAKATSANIS S, Panitsas F, Arapaki M, Galopoulos D, et al
    Serum ferritin levels in previously untreated classical Hodgkin lymphoma: correlations and prognostic significance.
    Leuk Lymphoma. 2022 Feb 19:1-14. doi: 10.1080/10428194.2021.2010054.
    PubMed     Abstract available

  45. OGASAWARA M, Miyashita M, Yamagishi Y, Ota S, et al
    Wilms' tumor 1 peptide-loaded dendritic cell vaccination in patients with relapsed or refractory malignant lymphoma.
    Leuk Lymphoma. 2022 Feb 15:1-5. doi: 10.1080/10428194.2022.2038371.

  46. CABIRTA A, Hidalgo-Gomez G, Marin-Niebla A, Gallur L, et al
    Variant t(11;22)(q13;q11.2) with IGL involvement in mantle cell lymphoma.
    Leuk Lymphoma. 2022 Feb 7:1-4. doi: 10.1080/10428194.2022.2034158.

  47. BOND DA, Huang Y, Christian BA, Jaglowski S, et al
    A phase I study of rituximab and buparlisib in patients with relapsed or refractory indolent non-Hodgkin lymphoma.
    Leuk Lymphoma. 2022 Feb 6:1-4. doi: 10.1080/10428194.2022.2034154.

  48. WANG A, Cirrone F, De Los Reyes FA, Papadopoulos J, et al
    High-dose methotrexate dosing strategy in primary central nervous system lymphoma.
    Leuk Lymphoma. 2022 Feb 4:1-8. doi: 10.1080/10428194.2021.2024818.
    PubMed     Abstract available

  49. MELODY M, Gandhi S, Saunders H, Abdel-Rahman Z, et al
    Incidence of thrombosis in relapsed/refractory B-cell lymphoma treated with axicabtagene ciloleucel: Mayo Clinic experience.
    Leuk Lymphoma. 2022 Feb 3:1-6. doi: 10.1080/10428194.2022.2030475.
    PubMed     Abstract available

  50. BAJWA A, Huang Y, Li R, Denlinger N, et al
    Prognostic value of early imaging following CAR-T cell therapy in diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2022 Feb 3:1-4. doi: 10.1080/10428194.2022.2032039.

  51. FISCHER T, Ni A, Bantilan KS, Soumerai JD, et al
    The impact of anti-CD20-based therapy on hypogammaglobulinemia in patients with follicular lymphoma.
    Leuk Lymphoma. 2022 Feb 3:1-10. doi: 10.1080/10428194.2021.2010058.
    PubMed     Abstract available

  52. LUCIJANIC M, Huzjan Korunic R, Sedinic M, Kovacevic S, et al
    Baseline and progressive adipopenia in newly diagnosed patients with diffuse large B-cell lymphoma with unfavorable features are associated with worse clinical outcomes.
    Leuk Lymphoma. 2022 Feb 2:1-10. doi: 10.1080/10428194.2022.2034160.
    PubMed     Abstract available

  53. NAKA R, Tada K, Kaneko H, Nagata O, et al
    Effectiveness and safety of R-GCD (rituximab, gemcitabine, carboplatin, and dexamethasone) for transplant-ineligible relapse/refractory diffuse large B-cell lymphoma and grade 3a follicular lymphoma: a retrospective analysis comparing with R-GDP (ritu
    Leuk Lymphoma. 2022 Feb 2:1-4. doi: 10.1080/10428194.2022.2032040.

    Ferritin, sex, and the wildfire of inflammation in Hodgkin lymphoma.
    Leuk Lymphoma. 2022 Feb 2:1-3. doi: 10.1080/10428194.2022.2034161.

  55. BELLESI S, Sali M, Maiolo E, Pereyra Boza MDC, et al
    Anti CD20-based immunochemotherapy abolishes antibody response to Covid-19 mRNA vaccine in lymphoma patients vaccinated during active first line treatment.
    Leuk Lymphoma. 2022 Feb 1:1-5. doi: 10.1080/10428194.2022.2032042.

  56. KADDU-MULINDWA D, Lesan V, Berdel C, Stilgenbauer S, et al
    Significant reduced loss of bone mineral density after four vs. six cycles of R-CHOP: an analysis of the FLYER-trial.
    Leuk Lymphoma. 2022;63:326-334.
    PubMed     Abstract available

  57. RAMBURAN A, Kriel R, Govender D
    Plasmablastic lymphomas show restricted EBV latency profile and MYC gene aberrations.
    Leuk Lymphoma. 2022;63:370-376.
    PubMed     Abstract available

  58. DUELL J, Obr A, Augustin M, Endell J, et al
    CD19 expression is maintained in DLBCL patients after treatment with tafasitamab plus lenalidomide in the L-MIND study.
    Leuk Lymphoma. 2022;63:468-472.

    January 2022
  59. CAMUS V, Viennot M, Leveque E, Viailly PJ, et al
    Circulating tumor DNA in primary mediastinal large B-cell lymphoma versus classical Hodgkin lymphoma: a retrospective study.
    Leuk Lymphoma. 2022 Jan 25:1-11. doi: 10.1080/10428194.2021.2010060.
    PubMed     Abstract available

  60. FERRARI A, Arniani S, Crescenzi B, Ascani S, et al
    High grade B-cell lymphoma with MYC, BCL2 and/or BCL6 rearrangements: unraveling the genetic landscape of a rare aggressive subtype of non-Hodgkin lymphoma.
    Leuk Lymphoma. 2022 Jan 19:1-7. doi: 10.1080/10428194.2021.2024821.
    PubMed     Abstract available

  61. KIM DW, Bukhari A, Lutfi F, Zafforoni F, et al
    Low utility of the H-Score and HLH-2004 criteria to identify patients with secondary hemophagocytic lymphohistiocytosis after CAR-T cell therapy for relapsed/refractory diffuse large B-Cell lymphoma.
    Leuk Lymphoma. 2022 Jan 19:1-9. doi: 10.1080/10428194.2021.2024817.
    PubMed     Abstract available

  62. WADA F, Shimomura Y, Kamijo K, Yamashita D, et al
    Prognostic impact of CD38 expression in relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma transformation.
    Leuk Lymphoma. 2022 Jan 19:1-4. doi: 10.1080/10428194.2021.2024820.

  63. PANAYIOTIDIS P, Tumyan G, Thieblemont C, Ptushkin VV, et al
    A phase-II study of atezolizumab in combination with obinutuzumab or rituximab for relapsed or refractory mantle cell or marginal zone lymphoma or Waldenstrom's macroglobulinemia.
    Leuk Lymphoma. 2022 Jan 19:1-12. doi: 10.1080/10428194.2021.2015765.
    PubMed     Abstract available

  64. CHOHAN K, Ansell SM
    Current salvage therapies in Hodgkin lymphoma.
    Leuk Lymphoma. 2022 Jan 17:1-14. doi: 10.1080/10428194.2021.2024819.
    PubMed     Abstract available

  65. MELEN CM, Merrien M, Wasik AM, Panagiotidis G, et al
    Clinical effects of a single dose of cannabinoids to patients with chronic lymphocytic leukemia.
    Leuk Lymphoma. 2022 Jan 17:1-11. doi: 10.1080/10428194.2021.2020776.
    PubMed     Abstract available

  66. HEGER JM, Borchmann S
    Coming of age: the evolving role of circulating tumor DNA in malignant lymphoma.
    Leuk Lymphoma. 2022 Jan 12:1-3. doi: 10.1080/10428194.2022.2027404.

  67. HYBEL TE, Vase MO, Lauridsen KL, Enemark MB, et al
    CD38 is a potential treatment target in lymphoma patients concurrently infected with human immunodeficiency virus.
    Leuk Lymphoma. 2022 Jan 12:1-5. doi: 10.1080/10428194.2021.2023741.

  68. CIOS KJ, Huda TI, Eakins RA, Mihyu MM, et al
    Specific TCR V-J gene segment recombinations leading to the identification pan-V-J CDR3s associated with survival distinctions: diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2022 Jan 12:1-9. doi: 10.1080/10428194.2021.2020781.
    PubMed     Abstract available

  69. BURGER JA, Robak T, Demirkan F, Bairey O, et al
    Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies.
    Leuk Lymphoma. 2022 Jan 11:1-12. doi: 10.1080/10428194.2021.2020779.
    PubMed     Abstract available

  70. HENRY M, Buck S, Al-Qanber B, Gadgeel M, et al
    Lymphocyte HLA-DR/CD-38 co-expression correlates with Hodgkin lymphoma cell cytotoxicity in vitro independent of PD-1/PD1-L pathway.
    Leuk Lymphoma. 2022 Jan 8:1-8. doi: 10.1080/10428194.2021.2023744.
    PubMed     Abstract available

  71. ABRAHAO R, Brunson AM, Kahn JM, Li QW, et al
    Second primary malignancy risk after Hodgkin lymphoma treatment among HIV-uninfected and HIV-infected survivors.
    Leuk Lymphoma. 2022 Jan 6:1-11. doi: 10.1080/10428194.2021.2020775.
    PubMed     Abstract available

  72. MINSON A, Hofman M, Dickinson M
    A PET in a time of need: toward early PET-adapted therapy in DLBCL in first relapse.
    Leuk Lymphoma. 2022;63:1-4.
    PubMed     Abstract available

  73. SEMCHENKOVA A, Zhogov V, Rudneva A, Potapenko L, et al
    Immune reconstitution following rituximab-based immunochemotherapy in pediatric patients with B-cell non-Hodgkin lymphomas.
    Leuk Lymphoma. 2022;63:217-221.

  74. COSTA PA, Espejo-Freire AP, Fan KC, Albini TA, et al
    Panuveitis induced by brentuximab vedotin: a possible novel adverse event of an antibody-drug conjugate.
    Leuk Lymphoma. 2022;63:239-242.

  75. OTHMAN T, Moskoff BN, Esteghamat N, Hoeg RT, et al
    Allogeneic hematopoietic cell transplantation using non-myeloablative ATG/TLI conditioning for lymphomas.
    Leuk Lymphoma. 2022;63:231-234.

  76. ZHANG Y, Seminario-Vidal L, Varnadoe C, Lu Y, et al
    Clinical characteristics and prognostic factors of 70 patients with Sezary syndrome: a single-institutional experience at Moffitt cancer center.
    Leuk Lymphoma. 2022;63:109-116.
    PubMed     Abstract available

  77. PIROSA MC, Zhang L, Hitz F, Novak U, et al
    A phase I trial of inotuzumab ozogamicin in combination with temsirolimus in patients with relapsed or refractory CD22-positive B-cell non-Hodgkin lymphomas.
    Leuk Lymphoma. 2022;63:117-123.
    PubMed     Abstract available

    December 2021
  78. GOUNI S, Strati P, Toruner G, Aradhya A, et al
    Statins enhance the chemosensitivity of R-CHOP in diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2021 Dec 31:1-12. doi: 10.1080/10428194.2021.2020782.
    PubMed     Abstract available

  79. NAKAMURA N, Kanemura N, Lee S, Fujita K, et al
    Prognostic impact of the controlling nutritional status score in patients with peripheral T-cell lymphoma.
    Leuk Lymphoma. 2021 Dec 29:1-8. doi: 10.1080/10428194.2021.2020777.
    PubMed     Abstract available

  80. FORTUNY J, Plana E, Kaye JA
    Serum lipid trajectories in the years before a lymphoma diagnosis.
    Leuk Lymphoma. 2021 Dec 29:1-13. doi: 10.1080/10428194.2021.1992618.
    PubMed     Abstract available

  81. LEBEL E, Vainstein V, Ashkenazi M, Zimran E, et al
    Neutrophil decline rate following autologous transplant for lymphoma is a predictor of patients' outcome.
    Leuk Lymphoma. 2021 Dec 29:1-8. doi: 10.1080/10428194.2021.2018580.
    PubMed     Abstract available

  82. AMAADOR K, Vos JMI, Pals ST, Kraan W, et al
    Discriminating between Waldenstrom macroglobulinemia and marginal zone lymphoma using logistic LASSO regression.
    Leuk Lymphoma. 2021 Dec 27:1-10. doi: 10.1080/10428194.2021.2018584.
    PubMed     Abstract available

  83. ZHANG C, Mi L, Wu M, Liu W, et al
    Angioimmunoblastic T-cell lymphoma: treatment strategies and prognostic factors from a retrospective multicenter study in China.
    Leuk Lymphoma. 2021 Dec 27:1-8. doi: 10.1080/10428194.2021.2015586.
    PubMed     Abstract available

  84. GIEFING M, Gearhart MD, Schneider M, Overbeck B, et al
    Loss of function mutations of BCOR in classical Hodgkin lymphoma.
    Leuk Lymphoma. 2021 Dec 27:1-11. doi: 10.1080/10428194.2021.2015587.
    PubMed     Abstract available

  85. DE GROOT FA, de Haan LM, de Groen RAL, Heijmen L, et al
    Synchronous diffuse large B-cell lymphoma and mantle cell lymphoma: support for low-threshold biopsies and genetic testing.
    Leuk Lymphoma. 2021 Dec 21:1-5. doi: 10.1080/10428194.2021.2015589.

  86. TRABOLSI A, Alderuccio JP, Florindez J, Rodriguez G, et al
    Marginal zone lymphoma of the colon: case series from a single center and SEER data review.
    Leuk Lymphoma. 2021 Dec 19:1-7. doi: 10.1080/10428194.2021.2015766.
    PubMed     Abstract available

  87. KORSOS V, Vallee A, Rys R, Probst S, et al
    Immune profiling of a patient with relapsed HIV-Related and EBV-positive diffuse large B-Cell lymphoma treated with pembrolizumab.
    Leuk Lymphoma. 2021 Dec 16:1-5. doi: 10.1080/10428194.2021.2012571.

  88. KUMAR AJ, Chao CR, Rodday AM, Chang H, et al
    Treatment patterns for relapsed and refractory Hodgkin lymphoma in a community oncology setting.
    Leuk Lymphoma. 2021 Dec 10:1-8. doi: 10.1080/10428194.2021.2012660.
    PubMed     Abstract available

  89. JAIN S, Bakhshi S, Seth R, Verma N, et al
    Risk based and response adapted radiation therapy for children and adolescents with newly diagnosed advanced stage Hodgkin lymphoma treated with ABVD chemotherapy: a report from the Indian pediatric oncology group study InPOG-HL-15-01.
    Leuk Lymphoma. 2021 Dec 9:1-8. doi: 10.1080/10428194.2021.2012659.
    PubMed     Abstract available

  90. HALWANI AS, Panizo C, Isufi I, Herrera AF, et al
    Phase 1/2 study of intratumoral G100 (TLR4 agonist) with or without pembrolizumab in follicular lymphoma.
    Leuk Lymphoma. 2021 Dec 6:1-13. doi: 10.1080/10428194.2021.2010057.
    PubMed     Abstract available

  91. SINGH V, Kim S, Deol A, Uberti JP, et al
    Allogeneic hematopoietic stem cell transplantation in T-cell lymphoma: a Meta-Analysis.
    Leuk Lymphoma. 2021 Dec 5:1-10. doi: 10.1080/10428194.2021.1999438.
    PubMed     Abstract available

  92. WITTE HM, Merz H, Bernd HW, Bauer A, et al
    Comparative analysis of international prognostic indices in gray-zone lymphoma.
    Leuk Lymphoma. 2021 Dec 2:1-9. doi: 10.1080/10428194.2021.2010067.
    PubMed     Abstract available

  93. GHAZZAUI N, Ferrad M, Issaoui H, Lecardeur S, et al
    HDAC recruitment in the IgH locus 3' regulatory region is different between mature B-cells and mature B-cell lymphomas.
    Leuk Lymphoma. 2021;62:3511-3515.

  94. STABER PB, Jurczak W, Greil R, Vucinic V, et al
    Tafasitamab combined with idelalisib or venetoclax in patients with CLL previously treated with a BTK inhibitor.
    Leuk Lymphoma. 2021;62:3440-3451.
    PubMed     Abstract available

  95. PEARSE WB, Petrich AM, Gordon LI, Karmali R, et al
    A phase I/II trial of brentuximab vedotin plus rituximab as frontline therapy for patients with immunosuppression-associated CD30+ and/or EBV + lymphomas.
    Leuk Lymphoma. 2021;62:3493-3500.
    PubMed     Abstract available

  96. WAGNER-JOHNSTON ND, Sharman J, Furman RR, Salles G, et al
    Idelalisib immune-related toxicity is associated with improved treatment response.
    Leuk Lymphoma. 2021;62:2915-2920.
    PubMed     Abstract available

  97. MINSON A, Dickinson M
    Glofitamab CD20-TCB bispecific antibody.
    Leuk Lymphoma. 2021;62:3098-3108.
    PubMed     Abstract available

    November 2021
  98. MOZAS P, Rivero A, Rivas-Delgado A, Nadeu F, et al
    The Prognostic Nutritional Index (PNI) is an independent predictor of overall survival in older patients with follicular lymphoma.
    Leuk Lymphoma. 2021 Nov 29:1-8. doi: 10.1080/10428194.2021.2010064.
    PubMed     Abstract available

  99. LIU H, Li P, Zhao A, Lei W, et al
    Incidence and prophylaxis of herpes zoster in relapsed or refractory B-cell lymphoma patients after CD19-specific CAR-T cell therapy.
    Leuk Lymphoma. 2021 Nov 28:1-4. doi: 10.1080/10428194.2021.2010062.

  100. GORDON MJ, Westin JR
    Fitting double-hit lymphoma into the aggressive lymphoma spectrum: a square peg in a round hole?
    Leuk Lymphoma. 2021 Nov 28:1-11. doi: 10.1080/10428194.2021.2008383.
    PubMed     Abstract available

  101. PAK TK, Dixon BN, Buege MJ, Dao PH, et al
    Successful implementation of outpatient R +/- DHAX (rituximab, dexamethasone, oxaliplatin, cytarabine) for select patients with lymphoma: a single-center experience.
    Leuk Lymphoma. 2021 Nov 16:1-9. doi: 10.1080/10428194.2021.2002318.
    PubMed     Abstract available

  102. SESHADRI MR, Melnick AM
    Targeting MALT1 for the treatment of diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2021 Nov 16:1-10. doi: 10.1080/10428194.2021.1999444.
    PubMed     Abstract available

  103. SHAH H, Jang H, Singh P, Kosti J, et al
    Improved post-ASCT survival of relapsed/refractory classical Hodgkin lymphoma patients in the era of novel agents.
    Leuk Lymphoma. 2021 Nov 15:1-8. doi: 10.1080/10428194.2021.2002322.
    PubMed     Abstract available

  104. SOLEIMANI A, Navarro A, Liu D, Herman SEM, et al
    CD5-negative mantle cell lymphoma: clinicopathologic features of an indolent variant that confers a survival advantage.
    Leuk Lymphoma. 2021 Nov 15:1-7. doi: 10.1080/10428194.2021.2002317.
    PubMed     Abstract available

  105. MELANI C, Wilson WH
    Front-Line treatment of diffuse large B-Cell lymphoma in patients with cardiovascular comorbidities; omission of anthracycline reduces cure.
    Leuk Lymphoma. 2021 Nov 11:1-3. doi: 10.1080/10428194.2021.2002323.

  106. REISS SN, Yerram P, Modelevsky L, Grommes C, et al
    Rituximab, Methotrexate, Carmustine, Etoposide, and Prednisone (RMBVP) for the treatment of relapsed/refractory primary central nervous system lymphoma: a retrospective single-center study.
    Leuk Lymphoma. 2021 Nov 10:1-6. doi: 10.1080/10428194.2021.1998481.
    PubMed     Abstract available

  107. LI M, Ding N, Mi L, Shi Y, et al
    Liquid biopsy in diffuse large B-cell lymphoma: utility in cell origin determination and survival prediction in Chinese patients.
    Leuk Lymphoma. 2021 Nov 9:1-10. doi: 10.1080/10428194.2021.1999441.
    PubMed     Abstract available

  108. MACKLIN-DOHERTY A, Jones M, Coulson P, Bruce C, et al
    Risk of thyroid disorders in adult and childhood Hodgkin lymphoma survivors 40 years after treatment.
    Leuk Lymphoma. 2021 Nov 5:1-11. doi: 10.1080/10428194.2021.1999445.
    PubMed     Abstract available

  109. AVGERINOU G, Stefanaki K, Liapis K, Kostopoulos IV, et al
    Fish evaluation of additional cytogenetic aberrations and hyperdiploidy in childhood Burkitt lymphoma.
    Leuk Lymphoma. 2021 Nov 2:1-11. doi: 10.1080/10428194.2021.1998480.
    PubMed     Abstract available

  110. LEVY A, Guidez S, Debiais C, Princet I, et al
    Waldenstrom macroglobulinemia and relationship to immune deficiency.
    Leuk Lymphoma. 2021;62:2665-2670.
    PubMed     Abstract available

    October 2021
  111. AUSSEDAT G, Maucort-Boulch D, Rey P, Safar V, et al
    Rituximab in combination with adapted-dose of ifosfamide and etoposide as salvage treatment in elderly refractory/relapsed diffuse large B-cell lymphoma patients non-candidate for high dose therapy: a retrospective study.
    Leuk Lymphoma. 2021 Oct 31:1-9. doi: 10.1080/10428194.2021.1998483.
    PubMed     Abstract available

  112. KIM HD, Cho H, Sohn BS, Park CS, et al
    Prognostic significance of serum beta2-microglobulin levels in patients with peripheral T-cell lymphoma not otherwise specified.
    Leuk Lymphoma. 2021 Oct 26:1-7. doi: 10.1080/10428194.2021.1971220.
    PubMed     Abstract available

  113. MUSIU P, Quattrocchi L, Barberi W, Della Starza I, et al
    Donor cell derived mantle cell lymphoma in a HSCT sibling donor-recipient pair: intrinsic biological clock in lymphomagenesis.
    Leuk Lymphoma. 2021 Oct 25:1-4. doi: 10.1080/10428194.2021.1984456.

  114. IYER SG, Kuker R, Florindez JA, Saul E, et al
    A single-center analysis of patients with extranodal marginal zone lymphoma of the breast.
    Leuk Lymphoma. 2021 Oct 21:1-8. doi: 10.1080/10428194.2021.1992764.
    PubMed     Abstract available

  115. PUCKRIN R, Ghosh S, Peters A, Stewart D, et al
    Inferior outcomes with R-CEOP for patients with diffuse large B-cell lymphoma and cardiovascular comorbidities.
    Leuk Lymphoma. 2021 Oct 21:1-8. doi: 10.1080/10428194.2021.1992762.
    PubMed     Abstract available

  116. KONG D, Li Y, Fu C, Hou M, et al
    Bortezomib provides favorable efficacy in type 3 acquired von willebrand syndrome related to lymphoplasmacytic lymphoma/Waldenstrom's macroglobulinemia.
    Leuk Lymphoma. 2021 Oct 20:1-4. doi: 10.1080/10428194.2021.1992766.

  117. NG DZ, Lee CY, Lam WW, Tong AK, et al
    Prognostication of diffuse large B-cell lymphoma patients with Deauville score of 3 or 4 at end-of-treatment PET evaluation: a comparison of the Deauville 5-point scale and the DeltaSUVmax method.
    Leuk Lymphoma. 2021 Oct 19:1-4. doi: 10.1080/10428194.2021.1992624.
    PubMed     Abstract available

  118. YIN G, Man C, Cheng W, Gao X, et al
    The prevalence and prognosis of hyponatraemia in non-Hodgkin lymphoma-associated hemophagocytic lymphohistiocytosis.
    Leuk Lymphoma. 2021 Oct 18:1-8. doi: 10.1080/10428194.2021.1992623.
    PubMed     Abstract available

  119. ARCARI A, Morello L, Vallisa D, Marcheselli L, et al
    Allogeneic stem cell transplantation in patients with mantle cell lymphoma: results from the MANTLE-FIRST study on behalf of Fondazione Italiana Linfomi.
    Leuk Lymphoma. 2021 Oct 8:1-10. doi: 10.1080/10428194.2021.1961238.
    PubMed     Abstract available

  120. LEBLANC MR, Zimmerman S, LeBlanc TW, Bryant AL, et al
    Persistent fatigue among long-term non-Hodgkin lymphoma survivors.
    Leuk Lymphoma. 2021 Oct 6:1-9. doi: 10.1080/10428194.2021.1984450.
    PubMed     Abstract available

  121. MALFONA F, Testi AM, Moleti ML, Petrucci L, et al
    Efficacy of ibrutinib as salvage treatment in a secondary central nervous system lymphoma (SCNSL) progressed after chemorefractory Primary Mediastinal B Cell Lymphoma (PMBCL).
    Leuk Lymphoma. 2021 Oct 6:1-4. doi: 10.1080/10428194.2021.1978091.

  122. TARIQ H, Pearse W, Moravek MR, Gao J, et al
    Refractory hemophagocytic lymphohistiocytosis in an adult patient with occult ALK-Positive anaplastic large cell lymphoma and a heterozygous MEFV mutation.
    Leuk Lymphoma. 2021 Oct 6:1-4. doi: 10.1080/10428194.2021.1984458.

  123. KLAIRMONT MM, Ward N
    Co-occurring rearrangements of DUSP22 and TP63 define a rare genetic subset of ALK-negative anaplastic large cell lymphoma with inferior survival outcomes.
    Leuk Lymphoma. 2021 Oct 6:1-3. doi: 10.1080/10428194.2021.1984457.

  124. KOO RM, Ritchie D
    Self-reliance or the generosity of others?: autologous versus allogeneic stem cell transplantation in high-risk Hodgkin lymphoma.
    Leuk Lymphoma. 2021;62:2303-2305.

  125. BRUMFIEL CM, Patel MH, DiCaudo DJ, Rosenthal AC, et al
    Recurrence of primary cutaneous CD30-positive lymphoproliferative disorder following COVID-19 vaccination.
    Leuk Lymphoma. 2021;62:2554-2555.

    September 2021
  126. ZHANG H, Liu M, Li Q, Lyu C, et al
    Evaluation of the safety and efficacy of humanized anti-CD19 chimeric antigen receptor T-cell therapy in older patients with relapsed/refractory diffuse large B-cell lymphoma based on the comprehensive geriatric assessment system.
    Leuk Lymphoma. 2021 Sep 29:1-9. doi: 10.1080/10428194.2021.1986216.
    PubMed     Abstract available

    Closing the diagnostic gap: increasing recognition of bone mineral density loss after treatment of lymphoma.
    Leuk Lymphoma. 2021 Sep 29:1-2. doi: 10.1080/10428194.2021.1984461.

  128. ALDERUCCIO JP, Lossos IS
    NOTCH signaling in the pathogenesis of splenic marginal zone lymphoma-opportunities for therapy.
    Leuk Lymphoma. 2021 Sep 29:1-12. doi: 10.1080/10428194.2021.1984452.
    PubMed     Abstract available

  129. MALPICA L, Castro D, Enriquez DJ, Oviedo-Pecho R, et al
    An international, multicenter, retrospective study on the positive impact of cutaneous involvement on the clinical outcome of adult T-cell leukemia/lymphoma.
    Leuk Lymphoma. 2021 Sep 29:1-11. doi: 10.1080/10428194.2021.1984455.
    PubMed     Abstract available

  130. SAWALHA Y, Radivoyevitch T, Jia X, Tullio K, et al
    The impact of socioeconomic disparities on the use of upfront autologous stem cell transplantation for mantle cell lymphoma.
    Leuk Lymphoma. 2021 Sep 15:1-9. doi: 10.1080/10428194.2021.1978085.
    PubMed     Abstract available

  131. GONZALEZ DE VILLAMBROSIA S, Bastos M, Palanca JM, Cruz JG, et al
    BCL2 translocation in high grade B cell lymphoma (NOS, DH/TH) is associated with reduced progression free survival.
    Leuk Lymphoma. 2021 Sep 11:1-8. doi: 10.1080/10428194.2021.1975189.
    PubMed     Abstract available

  132. KANAS G, Ge W, Quek RGW, Keeven K, et al
    Epidemiology of diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) in the United States and Western Europe: population-level projections for 2020-2025.
    Leuk Lymphoma. 2021 Sep 11:1-10. doi: 10.1080/10428194.2021.1975188.
    PubMed     Abstract available

  133. HSU A, Kurt H, Zayac AS, Olszewski AJ, et al
    CD5 expression in marginal zone lymphoma predicts differential response to rituximab or bendamustine/rituximab.
    Leuk Lymphoma. 2021 Sep 1:1-12. doi: 10.1080/10428194.2021.1973670.
    PubMed     Abstract available

    August 2021
  134. LOPEZ-GUILLERMO A, Canales MA, Dlouhy I, Mercadal S, et al
    A randomized phase II study comparing consolidation with a single dose of (90)Y ibritumomab tiuxetan vs. maintenance with rituximab for two years in patients with newly diagnosed follicular lymphoma responding to R-CHOP. Long-term follow-up results.
    Leuk Lymphoma. 2021 Aug 30:1-8. doi: 10.1080/10428194.2021.1971216.
    PubMed     Abstract available

  135. HSU CH, Yang CS, Chen YJ, Lin TL, et al
    Primary neurolymphomatosis in extranodal natural killer/T-cell lymphoma diagnosed by skin biopsy.
    Leuk Lymphoma. 2021 Aug 27:1-3. doi: 10.1080/10428194.2021.1971221.

  136. CHERNG HJ, Chuang HH, Steiner R, Fayad L, et al
    A prospective study on early PET/CT scans during the first cycle of salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2021 Aug 26:1-10. doi: 10.1080/10428194.2021.1971223.
    PubMed     Abstract available

  137. LANDSBURG DJ, Nasta SD, Gerson JN, Svoboda J, et al
    Time-to-response for patients with relapsed/refractory diffuse large B cell and high grade B cell lymphoma treated with polatuzumab-based therapy.
    Leuk Lymphoma. 2021 Aug 26:1-4. doi: 10.1080/10428194.2021.1971224.

  138. HANSENNE A, Camboni A, Van Den Neste E, Bailly S, et al
    Richter transformation heralded by EBV reactivation during ibrutinib therapy for chronic lymphocytic leukemia.
    Leuk Lymphoma. 2021 Aug 25:1-3. doi: 10.1080/10428194.2021.1964023.

  139. DENKER S, Bittner A, Frick M, Kase J, et al
    Ibrutinib- and bortezomib-extended R-CHOP induction in elderly higher-risk patients newly diagnosed with diffuse large B-cell lymphoma - first analysis of toxicity and efficacy signals.
    Leuk Lymphoma. 2021 Aug 20:1-9. doi: 10.1080/10428194.2021.1964024.
    PubMed     Abstract available

  140. ALDERUCCIO JP, Kuker RA, Barreto-Coelho P, Martinez BM, et al
    Prognostic value of presalvage metabolic tumor volume in patients with relapsed/refractory diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2021 Aug 20:1-11. doi: 10.1080/10428194.2021.1966786.
    PubMed     Abstract available

  141. AKYUZ N, Penas EMM, Janjetovic S, Loges S, et al
    Molecular- and cytogenetic characterization of the IGH associated t(1;14) in a nodal marginal zone B-cell lymphoma case.
    Leuk Lymphoma. 2021 Aug 18:1-5. doi: 10.1080/10428194.2021.1966783.

  142. WOYACH J, Tedeschi A, Munir T, Siddiqi T, et al
    Using ibrutinib in earlier lines of treatment results in better outcomes for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Leuk Lymphoma. 2021 Aug 13:1-5. doi: 10.1080/10428194.2021.1957871.

  143. AL ROWAIS F, Al Rabeh R, Al Mahasnah E, Al Shami A, et al
    Promising activity of single agent nivolumab followed by low-dose whole brain radiotherapy in isolated central nervous system relapse of Hodgkin lymphoma.
    Leuk Lymphoma. 2021 Aug 12:1-4. doi: 10.1080/10428194.2021.1964025.

  144. BENDIG S, Walter W, Meggendorfer M, Bar C, et al
    Whole genome sequencing demonstrates substantial pathophysiological differences of MYC rearrangements in patients with plasma cell myeloma and B-cell lymphoma.
    Leuk Lymphoma. 2021 Aug 12:1-10. doi: 10.1080/10428194.2021.1964021.
    PubMed     Abstract available

  145. NASTOUPIL LJ, Neelapu SS, Davis RE, Samaniego F, et al
    Preclinical and phase I studies of KA2237, a selective and potent inhibitor of PI3K beta/delta in relapsed refractory B cell lymphoma.
    Leuk Lymphoma. 2021 Aug 9:1-11. doi: 10.1080/10428194.2021.1957874.
    PubMed     Abstract available

  146. JOHNSON WT, Kartan S, Sokol K, Nikbakht N, et al
    Clinical characteristics and outcomes of black patients with mycosis fungoides and Sezary syndrome: a subgroup analysis of the phase III MAVORIC trial.
    Leuk Lymphoma. 2021;62:1877-1883.
    PubMed     Abstract available

    July 2021
  147. PLATTEL WJ, Bergamasco A, Trinchese F, Gavini F, et al
    Effectiveness of brentuximab vedotin monotherapy in relapsed or refractory Hodgkin lymphoma: a systematic review and meta-analysis.
    Leuk Lymphoma. 2021 Jul 29:1-13. doi: 10.1080/10428194.2021.1957865.
    PubMed     Abstract available

  148. TOBIN JWD, Crothers A, Ma TE, Mollee P, et al
    A cost-effectiveness analysis of front-line treatment strategies in early-stage follicular lymphoma.
    Leuk Lymphoma. 2021 Jul 29:1-9. doi: 10.1080/10428194.2021.1957866.
    PubMed     Abstract available

  149. HORWITZ S, Zinzani PL, Bagot M, Kim YH, et al
    Lack of impact of type and extent of prior therapy on outcomes of mogamulizumab therapy in patients with cutaneous T cell lymphoma in the MAVORIC trial.
    Leuk Lymphoma. 2021 Jul 26:1-10. doi: 10.1080/10428194.2021.1953007.
    PubMed     Abstract available

  150. TAO Y, He X, Qin Y, Liu P, et al
    Low platelet/platelet distribution width and high platelet/lymphocyte ratio are adverse prognostic factors in patients with newly diagnosed advanced Hodgkin lymphoma.
    Leuk Lymphoma. 2021 Jul 23:1-11. doi: 10.1080/10428194.2021.1953015.
    PubMed     Abstract available

  151. DURANI U, Ansell SM
    CD5+ diffuse large B-cell lymphoma: a narrative review.
    Leuk Lymphoma. 2021 Jul 21:1-9. doi: 10.1080/10428194.2021.1953010.
    PubMed     Abstract available

  152. BAEK GT, Mathis NJ, Perissinotti AJ, Marini BL, et al
    Late-onset complications with bendamustine versus CHOP or CVP based chemoimmunotherapy in indolent Non-Hodgkin's lymphoma.
    Leuk Lymphoma. 2021 Jul 15:1-9. doi: 10.1080/10428194.2021.1953014.
    PubMed     Abstract available

  153. SONG Y, Li J, Wang S, Zhou Z, et al
    The promising outcome with simultaneous integrated boost intensity modulated radiotherapy in confined nasal extranodal NK/T-cell lymphoma.
    Leuk Lymphoma. 2021 Jul 14:1-8. doi: 10.1080/10428194.2021.1948035.
    PubMed     Abstract available

  154. LAPIERRE L, Pericart S, Protin C, Borel C, et al
    Nivolumab in refractory cerebral relapse of Hodgkin's lymphoma.
    Leuk Lymphoma. 2021 Jul 13:1-3. doi: 10.1080/10428194.2021.1950711.

  155. ALLIOUX F, Gandhi D, Vilque JP, Nganoa C, et al
    End-of-treatment (18)F-FDG PET/CT in diffuse large B cell lymphoma patients: DeltaSUV outperforms Deauville score.
    Leuk Lymphoma. 2021 Jul 5:1-9. doi: 10.1080/10428194.2021.1948028.
    PubMed     Abstract available

  156. WITTMANN DAYAGI T, Sherman G, Bielorai B, Adam E, et al
    Characteristics and risk factors of infections following CD28-based CD19 CAR-T cells.
    Leuk Lymphoma. 2021;62:1692-1701.
    PubMed     Abstract available

  157. MANSO R, Rodriguez-Perales S, Torres-Ruiz R, Santonja C, et al
    PD-L1 expression in peripheral T-cell lymphomas is not related to either PD-L1 gene amplification or rearrangements.
    Leuk Lymphoma. 2021;62:1648-1656.
    PubMed     Abstract available

    June 2021
  158. MOU E, Falchi L, Sundaram V, Abramson JS, et al
    Impact of initial biopsy type on the time to final diagnostic biopsy in patients with follicular lymphoma and suspected histologic transformation.
    Leuk Lymphoma. 2021 Jun 26:1-9. doi: 10.1080/10428194.2021.1941936.
    PubMed     Abstract available

  159. XIAO Z, Mo Y, Long W, Li R, et al
    Value of baseline and end of chemotherapy (18)F-FDG PET/CT in pediatric patients with Burkitt lymphoma.
    Leuk Lymphoma. 2021 Jun 24:1-9. doi: 10.1080/10428194.2021.1941933.
    PubMed     Abstract available

  160. ELGAAFARY S, Lopez C, Nagel I, Vater I, et al
    Molecular characterization of Burkitt lymphoma in the breast or ovary.
    Leuk Lymphoma. 2021 Jun 24:1-10. doi: 10.1080/10428194.2021.1907374.
    PubMed     Abstract available

  161. OU YC, Tang Z, Novotny W, Cohen A, et al
    Rationale for once-daily or twice-daily dosing of zanubrutinib in patients with mantle cell lymphoma.
    Leuk Lymphoma. 2021 Jun 23:1-13. doi: 10.1080/10428194.2021.1929961.
    PubMed     Abstract available

  162. CASTILLO JJ, Beltran BE, Malpica L, Marques-Piubelli ML, et al
    Anaplastic lymphoma kinase-positive large B-cell lymphoma (ALK + LBCL): a systematic review of clinicopathological features and management.
    Leuk Lymphoma. 2021 Jun 21:1-9. doi: 10.1080/10428194.2021.1941929.
    PubMed     Abstract available

  163. HUSBY S, Favero F, Rodriguez-Gonzalez FG, Sutton LA, et al
    Mutations known from B-cell lymphoid malignancies are not found in CD34(+) stem cells from patients with lymphoma.
    Leuk Lymphoma. 2021 Jun 21:1-4. doi: 10.1080/10428194.2021.1933473.

  164. MESSMER M, Wagner-Johnston N
    COVID-19 vaccination in patients on rituximab: a survey of lymphoma physicians at NCI designated cancer centers.
    Leuk Lymphoma. 2021 Jun 21:1-4. doi: 10.1080/10428194.2021.1941939.

  165. CHIHARA D, Larson MC, Robinson DP, Thompson CA, et al
    Body mass index and survival of patients with lymphoma.
    Leuk Lymphoma. 2021 Jun 14:1-8. doi: 10.1080/10428194.2021.1929956.
    PubMed     Abstract available

  166. KARALEXI MA, Pourtsidis A, Panagopoulou P, Moschovi M, et al
    Overall and event-free survival of childhood lymphoma in Greece: analysis of harmonized clinical data over a 24-year active registration period.
    Leuk Lymphoma. 2021 Jun 11:1-13. doi: 10.1080/10428194.2021.1907376.
    PubMed     Abstract available

  167. MOZESSOHN L, Zhang L, Odejide OO, Chen R, et al
    Prognostic value of disease risk score versus gait speed in older adults with lymphoma.
    Leuk Lymphoma. 2021 Jun 11:1-8. doi: 10.1080/10428194.2021.1938029.
    PubMed     Abstract available

  168. BRAM EDNERSSON S, Stern M, Fagman H, Nilsson-Ehle H, et al
    Proteomic analysis in diffuse large B-cell lymphoma identifies dysregulated tumor microenvironment proteins in non-GCB/ABC subtype patients.
    Leuk Lymphoma. 2021 Jun 11:1-14. doi: 10.1080/10428194.2021.1913147.
    PubMed     Abstract available

  169. MINSON A, Dickinson M
    Too much, or not enough? The enduring uncertainty of maintenance rituximab for transformed follicular lymphoma.
    Leuk Lymphoma. 2021 Jun 9:1-3. doi: 10.1080/10428194.2021.1938033.

  170. SORIGUE M, Sancho JM
    The lymphocyte-to-monocyte ratio in follicular lymphoma.
    Leuk Lymphoma. 2021 Jun 8:1-4. doi: 10.1080/10428194.2021.1929965.

  171. CHEN Q, Liu S, Zhang K, Yu B, et al
    Hsa-miR-372-5p regulates the NIMA related kinase 7 and IL-1beta release in NK/T-cell lymphoma.
    Leuk Lymphoma. 2021 Jun 3:1-9. doi: 10.1080/10428194.2021.1933472.
    PubMed     Abstract available

  172. RODRIGUES JM, Porwit A, Hassan M, Ek S, et al
    Targeted genomic investigations in a population-based cohort of mantle cell lymphoma reveal novel clinically relevant targets.
    Leuk Lymphoma. 2021 Jun 3:1-11. doi: 10.1080/10428194.2021.1933480.
    PubMed     Abstract available

  173. TREVINO KM, Martin P, Saracino R, Leonard JP, et al
    Unmet need for mental health services in indolent lymphoma: age differences over one-year post-diagnosis.
    Leuk Lymphoma. 2021;62:1370-1378.
    PubMed     Abstract available

  174. MOZAS P, Lopez-Guillermo A
    Response to: The lymphocyte-to-monocyte ratio in follicular lymphoma.
    Leuk Lymphoma. 2021 Jun 1:1-2. doi: 10.1080/10428194.2021.1933482.

  175. ALVAREZ E, Le T, Kahn J, Winestone L, et al
    Comorbidities and socioeconomic status are predictors of survival in children and young adults with Burkitt lymphoma.
    Leuk Lymphoma. 2021 Jun 1:1-7. doi: 10.1080/10428194.2021.1932873.

    May 2021
  176. FLORINDEZ JA, Alderuccio JP, Reis IM, Lossos IS, et al
    Primary thyroid lymphoma: survival analysis of SEER database (1995-2016).
    Leuk Lymphoma. 2021 May 27:1-4. doi: 10.1080/10428194.2021.1933479.

  177. ZHU X, Li W, Zhu J, Chen H, et al
    Influence of MTHFR C677T and A1298C polymorphisms on the survival of pediatric patients with non-Hodgkin lymphoma.
    Leuk Lymphoma. 2021 May 25:1-9. doi: 10.1080/10428194.2021.1927017.
    PubMed     Abstract available

  178. PALOMBA ML, Jun MP, Lymp J, Nguyen A, et al
    Postinfusion monitoring costs by site of care for patients with relapsed/refractory large B-cell lymphoma receiving third- or later-line treatment with lisocabtagene maraleucel in the TRANSCEND NHL 001 and OUTREACH trials.
    Leuk Lymphoma. 2021 May 21:1-8. doi: 10.1080/10428194.2021.1910686.
    PubMed     Abstract available

  179. BONZHEIM I, Quintanilla-Martinez L
    All activated signaling pathways lead to anaplastic large cell lymphoma (ALCL).
    Leuk Lymphoma. 2021 May 21:1-3. doi: 10.1080/10428194.2021.1924373.

  180. LIANG D, Wei C, Zhang X, Yang J, et al
    Efficacy of lenalidomide for relapsed or refractory T lymphoblastic lymphoma/leukemia after allogeneic hematopoietic stem cell transplantation.
    Leuk Lymphoma. 2021 May 17:1-5. doi: 10.1080/10428194.2021.1919665.

  181. CHAPMAN J, Verdun RE, Lossos IS
    Low LIM-domain only 2 (LMO2) expression in aggressive B cell lymphoma correlates with MYC and MYC/BCL2 rearrangements, especially in germinal center cell-type tumors.
    Leuk Lymphoma. 2021 May 14:1-4. doi: 10.1080/10428194.2021.1927020.

  182. FAKHRI B, Yilmaz E, Gao F, Ambinder RF, et al
    Survival after autologous versus allogeneic transplantation in patients with relapsed and refractory Hodgkin lymphoma.
    Leuk Lymphoma. 2021 May 14:1-8. doi: 10.1080/10428194.2021.1927016.
    PubMed     Abstract available

  183. MACHAN S, Rodriguez M, Alonso-Alonso R, Manso R, et al
    Subcutaneous panniculitis-like T-cell lymphoma, lupus erythematosus profundus, and overlapping cases: molecular characterization through the study of 208 genes.
    Leuk Lymphoma. 2021 May 8:1-11. doi: 10.1080/10428194.2021.1901098.
    PubMed     Abstract available

  184. YANG J, Zhang Y, Yang P, Zhang X, et al
    A novel nomogram based on prognostic factors for predicting venous thrombosis risk in lymphoma patients.
    Leuk Lymphoma. 2021 May 8:1-9. doi: 10.1080/10428194.2021.1913149.
    PubMed     Abstract available

  185. GOYAL RK, Jain P, Nagar SP, Le H, et al
    Real-world evidence on survival, adverse events, and health care burden in Medicare patients with mantle cell lymphoma.
    Leuk Lymphoma. 2021 May 8:1-10. doi: 10.1080/10428194.2021.1919662.
    PubMed     Abstract available

  186. AL FEGHALI KA, Fang P, Gule-Monroe M, Milgrom S, et al
    Prognostic value of disease distribution in secondary central nervous system diffuse large B cell lymphoma treated with radiation therapy.
    Leuk Lymphoma. 2021 May 4:1-8. doi: 10.1080/10428194.2021.1919656.
    PubMed     Abstract available

  187. LANG N, Kuruvilla J
    Evolving management strategies for lymphomas during the COVID-19 pandemic.
    Leuk Lymphoma. 2021;62:1046-1056.
    PubMed     Abstract available

  188. WAGNER-JOHNSTON ND, Schuster SJ, deVos S, Salles G, et al
    Outcomes of patients with up to 6 years of follow-up from a phase 2 study of idelalisib for relapsed indolent lymphomas.
    Leuk Lymphoma. 2021;62:1077-1087.
    PubMed     Abstract available

  189. SEKAR A, Davids MS
    Idelalisib in indolent NHL - has it finally found its niche?
    Leuk Lymphoma. 2021;62:1029-1030.

    April 2021
  190. LUCIJANIC M, Korunic RH, Sedinic M, Kusec R, et al
    Prognostic impact of psoas muscle index in patients with diffuse large B-cell lymphoma might be dependent on the immunochemotherapy type.
    Leuk Lymphoma. 2021 Apr 28:1-4. doi: 10.1080/10428194.2021.1919667.

  191. CARPIO C, Iacoboni G, Villacampa G, Catala E, et al
    Selection process and causes of non-eligibility for CD19 CAR-T cell therapy in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma in a European center.
    Leuk Lymphoma. 2021 Apr 24:1-4. doi: 10.1080/10428194.2021.1913141.

  192. GUPTA A, Gill S
    CAR-T cell persistence in the treatment of leukemia and lymphoma.
    Leuk Lymphoma. 2021 Apr 19:1-13. doi: 10.1080/10428194.2021.1913146.
    PubMed     Abstract available

  193. WILSON WH, Phillips T, Popplewell L, de Vos S, et al
    Phase 1b/2 study of ibrutinib and lenalidomide with dose-adjusted EPOCH-R in patients with relapsed/refractory diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2021 Apr 15:1-16. doi: 10.1080/10428194.2021.1907371.
    PubMed     Abstract available

  194. OLLIKAINEN RK, Kotkaranta PH, Kemppainen J, Teppo HR, et al
    Different chemokine profile between systemic and testicular diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2021 Apr 15:1-10. doi: 10.1080/10428194.2021.1913150.
    PubMed     Abstract available

    March 2021
  195. EPSTEIN-PETERSON ZD, Ganesan N, Barker JN, Drullinsky PR, et al
    Outcomes of adult T-Cell leukemia/lymphoma with allogeneic stem cell transplantation: single-institution experience.
    Leuk Lymphoma. 2021 Mar 29:1-7. doi: 10.1080/10428194.2021.1897806.
    PubMed     Abstract available

  196. WENGE DV, Wethmar K, Mikesch JH, Reicherts C, et al
    Allogeneic hematopoietic stem cell transplantation for therapy-related myeloid neoplasms following treatment of a lymphoid malignancy.
    Leuk Lymphoma. 2021 Mar 29:1-10. doi: 10.1080/10428194.2021.1894645.
    PubMed     Abstract available

  197. CAZELLES C, Belhadj K, Vellemans H, Camus V, et al
    Rituximab plus gemcitabine and oxaliplatin (R-GemOx) in refractory/relapsed diffuse large B-cell lymphoma: a real-life study in patients ineligible for autologous stem-cell transplantation.
    Leuk Lymphoma. 2021 Mar 25:1-8. doi: 10.1080/10428194.2021.1901090.
    PubMed     Abstract available

  198. URYU H, Mishima Y, Tsuyama N, Yokoyama M, et al
    Rituximab maintenance improves outcomes of transformed diffuse large B-cell lymphoma: a retrospective study of 519 cases with de novo diffuse large B-cell lymphoma and 62 cases with concurrent diffuse large B-cell lymphoma and follicular lymphoma.
    Leuk Lymphoma. 2021 Mar 21:1-10. doi: 10.1080/10428194.2021.1901091.
    PubMed     Abstract available

  199. BALAKRISHNA J, Basumallik N, Matulonis R, Scott D, et al
    Intensity of antigen expression reflects IGHV mutational status and Dohner-defined prognostic categories in chronic lymphocytic leukemia, monoclonal B-cell lymphocytosis, and small lymphocytic lymphoma.
    Leuk Lymphoma. 2021 Mar 18:1-12. doi: 10.1080/10428194.2021.1894641.
    PubMed     Abstract available

  200. WANG X, McIntosh L, Selove WJ, Zivny J, et al
    Pseudoprogression of triple-hit diffuse large B-cell lymphoma following polatuzumab vedotin-based salvage therapy.
    Leuk Lymphoma. 2021 Mar 15:1-4. doi: 10.1080/10428194.2021.1894646.

  201. GAO Y, Ding X
    miR-145-5p exerts anti-tumor effects in diffuse large B-cell lymphoma by regulating S1PR1/STAT3/AKT pathway.
    Leuk Lymphoma. 2021 Mar 13:1-8. doi: 10.1080/10428194.2021.1894642.
    PubMed     Abstract available

  202. SHIROUCHI Y, Yokoyama M, Fukuta T, Uryu H, et al
    Progression-free survival at 24 months as a predictor of survival outcomes after CHOP treatment in patients with peripheral T-cell lymphoma: a single-center validation study in a Japanese population.
    Leuk Lymphoma. 2021 Mar 10:1-12. doi: 10.1080/10428194.2021.1894649.
    PubMed     Abstract available

  203. MCCARTHY P, Harford J, O'Marcaigh A, Malone A, et al
    Ongoing excellent outcomes with reduced toxicities following integration of molecular targeted therapies in pediatric anaplastic large cell lymphoma.
    Leuk Lymphoma. 2021 Mar 8:1-5. doi: 10.1080/10428194.2021.1894644.

  204. TIAN Y, Li L, Lin G, Wang Y, et al
    lncRNA SNHG14 promotes oncogenesis and immune evasion in diffuse large-B-cell lymphoma by sequestering miR-152-3p.
    Leuk Lymphoma. 2021 Mar 8:1-15. doi: 10.1080/10428194.2021.1876866.
    PubMed     Abstract available

  205. FRECHET L, Woronoff AS, Gerazime A, Puzenat E, et al
    Primary cutaneous lymphoma: a population-based cancer registry descriptive study of 155 consecutive cases diagnosed between 1979 and 2016.
    Leuk Lymphoma. 2021 Mar 8:1-6. doi: 10.1080/10428194.2021.1891232.

  206. FANG X, Young KH
    Hepatitis B virus antibody status provides new insights in diffuse large B-Cell lymphoma.
    Leuk Lymphoma. 2021 Mar 2:1-4. doi: 10.1080/10428194.2021.1891233.

  207. ISSA DE, Dinmohamed AG, Wondergem MJ, Blommestein HM, et al
    A population-based study on different regimens of R-CHOP in patients with newly diagnosed DLBCL in The Netherlands.
    Leuk Lymphoma. 2021;62:549-559.
    PubMed     Abstract available

  208. BERNING P, Lenz G
    The role of PI3K inhibitors in the treatment of malignant lymphomas.
    Leuk Lymphoma. 2021;62:517-527.
    PubMed     Abstract available

    February 2021
  209. DANCE KV, Imbody CB, Chen L, McNeill L, et al
    Perceptions of clinical care and research among African-American patients with lymphoma.
    Leuk Lymphoma. 2021 Feb 28:1-13. doi: 10.1080/10428194.2021.1892092.
    PubMed     Abstract available

  210. LUAN D, Wu Y, Goldstein J, Rutherford S, et al
    Evaluation of the prognostic utility of bone marrow biopsy in diffuse large B-Cell lymphoma in the SEER-Medicare dataset.
    Leuk Lymphoma. 2021 Feb 25:1-14. doi: 10.1080/10428194.2021.1889540.
    PubMed     Abstract available

  211. NOEL N, Beaudonnet G, Cauquil C, Laurenge A, et al
    Inflammatory demyelinating polyneuropathies and lymphoma: clues to diagnosis and therapy.
    Leuk Lymphoma. 2021 Feb 24:1-9. doi: 10.1080/10428194.2021.1889535.

  212. SILVA O, Charu V, Ewalt MD, Metcalf RA, et al
    Classic Hodgkin lymphoma in Guatemalan children of age less than six years: analysis of immune regulatory pathways and the tumor microenvironment.
    Leuk Lymphoma. 2021 Feb 24:1-13. doi: 10.1080/10428194.2021.1885666.
    PubMed     Abstract available

  213. BINKLEY MS, Hiniker SM, Younes S, Yoo C, et al
    Stage I-II diffuse large B-cell lymphoma treated with rituximab and chemotherapy with or without radiotherapy.
    Leuk Lymphoma. 2021 Feb 23:1-15. doi: 10.1080/10428194.2021.1876859.
    PubMed     Abstract available

  214. YALAMANCHI M, Sharma A, Nguyen M, Truong J, et al
    Successful and durable response of primary CNS T-cell lymphoma to upfront temozolomide monotherapy.
    Leuk Lymphoma. 2021 Feb 21:1-5. doi: 10.1080/10428194.2021.1889538.

  215. DESAI S, Ansell SM
    Future directions in Hodgkin lymphoma: checkpoint inhibitors and beyond.
    Leuk Lymphoma. 2021 Feb 18:1-15. doi: 10.1080/10428194.2021.1885667.
    PubMed     Abstract available

  216. BONOMETTI A, Boveri E, Varettoni M, Ripamonti A, et al
    Systemic mastocytosis and lymphoplasmacytic lymphoma: an unusual and intriguing form of SM-AHN.
    Leuk Lymphoma. 2021 Feb 14:1-5. doi: 10.1080/10428194.2021.1885661.

  217. ORFALI N, Jhanwar Y, Koo C, Pasciolla M, et al
    Sequential intensive chemotherapy followed by autologous or allogeneic transplantation for refractory lymphoma.
    Leuk Lymphoma. 2021 Feb 13:1-15. doi: 10.1080/10428194.2021.1881516.
    PubMed     Abstract available

  218. SINATKAS V, Stathopoulou K, Xagoraris I, Ye J, et al
    MDMX/MDM4 is highly expressed and contributes to cell growth and survival in anaplastic large cell lymphoma.
    Leuk Lymphoma. 2021 Feb 11:1-11. doi: 10.1080/10428194.2021.1876871.
    PubMed     Abstract available

  219. ZHENG M, Zhou X, Wang Q, Chen X, et al
    Metabolomic approach to characterize the metabolic phenotypes and varied response to ouabain of diffuse large B-cell lymphoma cells.
    Leuk Lymphoma. 2021 Feb 10:1-18. doi: 10.1080/10428194.2021.1881513.
    PubMed     Abstract available

  220. MILGROM SA, Dabaja BS, Mikhaeel NG
    Advanced-stage Hodgkin lymphoma: have effective therapy and modern imaging changed the significance of bulky disease?
    Leuk Lymphoma. 2021 Feb 7:1-19. doi: 10.1080/10428194.2021.1881515.
    PubMed     Abstract available

  221. RAJAMAKI A, Sunela K, Prusila REI, Kuusisto MEL, et al
    Female patients with follicular lymphoma have a better prognosis if primary remission lasts over 24 months.
    Leuk Lymphoma. 2021 Feb 5:1-9. doi: 10.1080/10428194.2021.1872073.
    PubMed     Abstract available

    January 2021
  222. CAMPBELL BA, Khot A
    "RT or not RT?" The question for early-stage peripheral T-cell lymphoma.
    Leuk Lymphoma. 2021 Jan 29:1-4. doi: 10.1080/10428194.2021.1876873.

  223. JAIME-PEREZ JC, Hernandez-Coronado M, Picon-Galindo E, Salazar-Cavazos L, et al
    Results of a completely outpatient autologous stem cell transplant program for lymphoma patients receiving reduced-intensity conditioning.
    Leuk Lymphoma. 2021 Jan 24:1-10. doi: 10.1080/10428194.2021.1876870.
    PubMed     Abstract available

  224. AUGUSTYN A, Medeiros LJ, Ludmir EB, Gunther J, et al
    The impact of cell-of-origin, MYC/Bcl-2 dual expression and MYC rearrangement on disease relapse among early stage diffuse large B-cell lymphoma patients treated with combined modality therapy.
    Leuk Lymphoma. 2021 Jan 22:1-12. doi: 10.1080/10428194.2020.1869965.
    PubMed     Abstract available

  225. LOPEZ-ALONSO R, Qi S, Mashiach T, Weiler-Sagie M, et al
    The presence of a bulky mediastinal mass of 7 cm or greater in diameter confers an adverse prognosis to patients with advanced Hodgkin lymphoma in case of negative interim PET/CT.
    Leuk Lymphoma. 2021 Jan 22:1-18. doi: 10.1080/10428194.2021.1872069.
    PubMed     Abstract available

  226. MARQUES MO, Manso PG, Araujo RLC, Brito FDN, et al
    Long-term outcomes of ocular adnexal lymphomas: case series from two lymphoma centers in Brazil.
    Leuk Lymphoma. 2021 Jan 18:1-5. doi: 10.1080/10428194.2020.1855348.

  227. LYONS RM, Shtivelband M, Kingsley E, Moezi M, et al
    Efficacy and safety of ofatumumab and bendamustine followed by ofatumumab maintenance in patients with relapsed indolent non-Hodgkin lymphoma after prior rituximab.
    Leuk Lymphoma. 2021 Jan 15:1-8. doi: 10.1080/10428194.2020.1869957.
    PubMed     Abstract available

  228. CHERNG HJ, Westin J
    Why R-CHOP + X is not enough: lessons learned and next steps in the mission to improve frontline therapy for diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2021 Jan 6:1-17. doi: 10.1080/10428194.2020.1869228.
    PubMed     Abstract available

  229. HU S, Chen N, Lu K, Zhen C, et al
    The prognostic roles of hepatitis B virus antibody in diffuse large B-cell lymphoma patients.
    Leuk Lymphoma. 2021 Jan 5:1-15. doi: 10.1080/10428194.2020.1867726.
    PubMed     Abstract available

  230. POLPRASERT C, Takeuchi Y, Makishima H, Wudhikarn K, et al
    Frequent mutations in HLA and related genes in extranodal NK/T cell lymphomas.
    Leuk Lymphoma. 2021;62:95-103.
    PubMed     Abstract available

  231. VOORHEES TJ, Kannan KK, Galeotti J, Grover N, et al
    Identification of high-risk monomorphic post-transplant lymphoproliferative disorder following solid organ transplantation.
    Leuk Lymphoma. 2021;62:86-94.
    PubMed     Abstract available

    December 2020
  232. MIAN A, Wei W, Winter AM, Khouri J, et al
    Outcomes and factors impacting use of axicabtagene ciloleucel in patients with relapsed or refractory large B-cell lymphoma: results from an intention-to-treat analysis.
    Leuk Lymphoma. 2020 Dec 29:1-9. doi: 10.1080/10428194.2020.1864349.
    PubMed     Abstract available

  233. DABAJA BS, Milgrom SA, Wirth A
    Secondary central nervous system diffuse large cell lymphoma: an opportunity for radiation therapy to improve outcomes.
    Leuk Lymphoma. 2020 Dec 25:1-4. doi: 10.1080/10428194.2020.1864353.

  234. NORDMO C, Glehr G, Altenbuchinger M, Spang R, et al
    Identification of a miRNA based model to detect prognostic subgroups in patients with aggressive B-cell lymphoma.
    Leuk Lymphoma. 2020 Dec 22:1-15. doi: 10.1080/10428194.2020.1861268.
    PubMed     Abstract available

  235. SZAFER-GLUSMAN E, Liu J, Sinha A, Peale FV Jr, et al
    Evaluation of the effect of prospective biomarker testing on progression-free survival in diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2020 Dec 16:1-4. doi: 10.1080/10428194.2020.1849674.

  236. ILTAR U, Sozel H, Sozel YK, Atas U, et al
    Prognostic impact of the psoas muscle index, a parameter of sarcopenia, in patients with diffuse large B-cell lymphoma treated with rituximab-based chemoimmunotherapy.
    Leuk Lymphoma. 2020 Dec 10:1-9. doi: 10.1080/10428194.2020.1856833.
    PubMed     Abstract available

  237. BARRIENTOS JC, Hillmen P, Salles G, Sharman J, et al
    No increased bleeding events in patients with relapsed chronic lymphocytic leukemia and indolent non-Hodgkin lymphoma treated with idelalisib.
    Leuk Lymphoma. 2020 Dec 10:1-9. doi: 10.1080/10428194.2020.1845339.
    PubMed     Abstract available

  238. TEXTE E, Lequesne J, Tilly H, Jardin F, et al
    SUVmax-based assessment of PET response shows a superior specificity to Deauville criteria for predicting recurrence in Hodgkin's lymphoma.
    Leuk Lymphoma. 2020 Dec 8:1-14. doi: 10.1080/10428194.2020.1855341.
    PubMed     Abstract available

  239. VELA-OJEDA J, Perez-Retiguin FDC, Olivas-Bejarano AC, Garcia-Ruiz Esparza MA, et al
    Clinical relevance of NKT cells and soluble MIC-A in Hodgkin lymphoma.
    Leuk Lymphoma. 2020 Dec 7:1-12. doi: 10.1080/10428194.2020.1852473.
    PubMed     Abstract available

  240. GEEL JA, Eyal KC, Hendricks MG, Myezo KH, et al
    Prognostic factors affecting survival in children and adolescents with HIV and Hodgkin lymphoma in South Africa.
    Leuk Lymphoma. 2020 Dec 7:1-14. doi: 10.1080/10428194.2020.1852472.
    PubMed     Abstract available

  241. POVEDA J, Cassidy DP, Zhou Y, Alderuccio JP, et al
    Expression of germinal center cell markers by extranodal marginal zone lymphomas of MALT type within colonized follicles, a diagnostic pitfall with follicular lymphoma.
    Leuk Lymphoma. 2020 Dec 7:1-7. doi: 10.1080/10428194.2020.1855347.
    PubMed     Abstract available

  242. FOX TA, Carpenter B, Taj M, Perisoglou M, et al
    Utility of 18F-FDG-PET/CT in lymphoblastic lymphoma.
    Leuk Lymphoma. 2020 Dec 4:1-6. doi: 10.1080/10428194.2020.1855346.

  243. MORIGI A, Casadei B, Argnani L, Stefoni V, et al
    Successful stem cell harvest and autologous transplantation in a patient with cold agglutinin syndrome and aggressive lymphoma.
    Leuk Lymphoma. 2020 Dec 4:1-3. doi: 10.1080/10428194.2020.1855342.

  244. DI ROCCO A, Cuneo A, Di Rocco A, Merli F, et al
    Relapsed/refractory diffuse large B-cell lymphoma patients. A multicenter retrospective analysis of eligibility criteria for car-T cell therapy.
    Leuk Lymphoma. 2020 Dec 4:1-11. doi: 10.1080/10428194.2020.1849676.
    PubMed     Abstract available

  245. BALLAS LK, Metzger ML, Milgrom SA, Advani R, et al
    Nodular lymphocyte predominant Hodgkin lymphoma: executive summary of the American radium society appropriate use criteria.
    Leuk Lymphoma. 2020 Dec 4:1-14. doi: 10.1080/10428194.2020.1852559.
    PubMed     Abstract available

  246. PARKS AL, Kambhampati S, Fakhri B, Andreadis C, et al
    Incidence, management and outcomes of arterial and venous thrombosis after chimeric antigen receptor modified T cells for B cell lymphoma and multiple myeloma.
    Leuk Lymphoma. 2020 Dec 1:1-6. doi: 10.1080/10428194.2020.1852474.

    November 2020
  247. RODRIGUEZ-LOPEZ JL, Patel AK, Balasubramani GK, Glaser SM, et al
    Treatment selection and survival outcomes in Early-Stage peripheral T-Cell lymphomas: does anaplastic lymphoma kinase mutation impact the benefit of consolidative radiotherapy?
    Leuk Lymphoma. 2020 Nov 30:1-11. doi: 10.1080/10428194.2020.1842398.
    PubMed     Abstract available

  248. VOCKOVA P, Molinsky J, Klanova M, Karban J, et al
    CD31/PECAM-1 impacts engraftment, growth and spread of mantle cell lymphoma cells and positively correlates with extramedullary involvement.
    Leuk Lymphoma. 2020 Nov 25:1-8. doi: 10.1080/10428194.2020.1849678.
    PubMed     Abstract available

  249. CHASE ML, Merryman R, Fisher DC, Jacobsen E, et al
    A prospective study of minimal residual disease in patients with diffuse large B-cell lymphoma using an Ig-NGS assay.
    Leuk Lymphoma. 2020 Nov 25:1-4. doi: 10.1080/10428194.2020.1830390.

  250. PAPADAKIS V, Efstathopoulou M, Angelopoulou MK, Tsourouflis G, et al
    Curative surgery in highly selected patients with heavily pretreated, relapsed/refractory classical Hodgkin lymphoma.
    Leuk Lymphoma. 2020 Nov 25:1-5. doi: 10.1080/10428194.2020.1842404.

  251. COX MC, Nusca SM, Di Landro F, Marsilli G, et al
    Exercise training (ET) in adult and elderly patients receiving anti-lymphoma treatments is feasible and may improve the provision of care.
    Leuk Lymphoma. 2020 Nov 24:1-11. doi: 10.1080/10428194.2020.1842396.
    PubMed     Abstract available

  252. MENG G, Wang Y, Wang J, Wang Z, et al
    The DEP regimen is superior to the HLH-1994 regimen as first-line therapy for lymphoma-associated haemophagocytic lymphohistiocytosis.
    Leuk Lymphoma. 2020 Nov 21:1-13. doi: 10.1080/10428194.2020.1849671.
    PubMed     Abstract available

  253. SCOTT AJ, Tokaz MC, Shango M, Devata S, et al
    Clinical application of next generation sequencing in lymphoma.
    Leuk Lymphoma. 2020 Nov 16:1-6. doi: 10.1080/10428194.2020.1846734.
    PubMed     Abstract available

  254. YAMASAKI S, Iida H, Yoshida I, Komeno T, et al
    Comparison of prognostic scores in transplant-ineligible patients with peripheral T-cell lymphoma not otherwise specified and angioimmunoblastic T-cell lymphoma: a retrospective study from the national hospital organization in Japan.
    Leuk Lymphoma. 2020 Nov 9:1-9. doi: 10.1080/10428194.2020.1845336.
    PubMed     Abstract available

  255. CHEN MT, Fu XH, Huang H, Wang Z, et al
    Combination of crizotinib and chemotherapy in patients with relapsed or refractory anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL).
    Leuk Lymphoma. 2020 Nov 6:1-10. doi: 10.1080/10428194.2020.1839658.
    PubMed     Abstract available

  256. PAN J, Ghimire S, Alpdogan SO, Chapman A, et al
    Phase I/II study of bendamustine in combination with ofatumumab, carboplatin, etoposide (BOCE) for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma.
    Leuk Lymphoma. 2020 Nov 4:1-8. doi: 10.1080/10428194.2020.1842400.
    PubMed     Abstract available

  257. HARKINS RA, Flowers CR
    How should clinicians interpret conflicting cost-effectiveness analyses for the treatment of lymphoma across nations and payer models?
    Leuk Lymphoma. 2020 Nov 4:1-4. doi: 10.1080/10428194.2020.1837798.

  258. COLEMAN M, Belada D, Casasnovas RO, Gressin R, et al
    Phase 2 study of parsaclisib (INCB050465), a highly selective, next-generation PI3Kdelta inhibitor, in relapsed or refractory diffuse large B-cell lymphoma (CITADEL-202).
    Leuk Lymphoma. 2020 Nov 3:1-9. doi: 10.1080/10428194.2020.1832660.
    PubMed     Abstract available

  259. MADSEN C, Plesner TL, Bentzen HH, Jorgensen J, et al
    Real world data on histological transformation in patients with follicular lymphoma: incidence, clinico-pathological risk factors and outcome in a nationwide Danish cohort.
    Leuk Lymphoma. 2020;61:2584-2594.
    PubMed     Abstract available

  260. LEWIS KL, Cheah CY
    Event free survival at 12 months (EFS12) in stage 1 DLBCL - a reassuring milestone?
    Leuk Lymphoma. 2020;61:2542-2543.

    October 2020
  261. MOERDLER S, Ewart M, Friedman DL, Kelly K, et al
    LAG-3 is expressed on a majority of tumor infiltrating lymphocytes in pediatric Hodgkin lymphoma.
    Leuk Lymphoma. 2020 Oct 28:1-8. doi: 10.1080/10428194.2020.1839651.
    PubMed     Abstract available

  262. BLANSKY D, Fazzari M, Mantzaris I, Rohan T, et al
    Racial and ethnic differences in diffuse large B-cell lymphoma survival among an underserved, urban population.
    Leuk Lymphoma. 2020 Oct 28:1-9. doi: 10.1080/10428194.2020.1839656.
    PubMed     Abstract available

  263. RODGERS TD, Williams AM, Baran A, Reagan PM, et al
    Toxicity patterns of novel PI3K combinations in patients with non-Hodgkin lymphoma.
    Leuk Lymphoma. 2020 Oct 25:1-8. doi: 10.1080/10428194.2020.1837796.
    PubMed     Abstract available

  264. HAMDI L, Creidy R, Boudjemaa S, Hendel-Chavez H, et al
    Frequent altered distribution of peripheral B-lymphocyte subsets in pediatric and adolescent patients with classical Hodgkin lymphoma.
    Leuk Lymphoma. 2020 Oct 23:1-8. doi: 10.1080/10428194.2020.1834090.
    PubMed     Abstract available

  265. YOUNES S, Natkunam Y
    FOXes at play in the lymphoma landscape.
    Leuk Lymphoma. 2020 Oct 16:1-3. doi: 10.1080/10428194.2020.1834099.

  266. PAN BH, Kong YL, Wang L, Zhu HY, et al
    The prognostic roles of hypogammaglobulinemia and hypocomplementemia in newly diagnosed diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2020 Oct 16:1-9. doi: 10.1080/10428194.2020.1832673.
    PubMed     Abstract available

  267. LEHRICH BM, Goshtasbi K, Abiri A, Yasaka TM, et al
    Treatment modalities and overall survival outcomes for sinonasal extranodal natural killer/T-cell lymphoma.
    Leuk Lymphoma. 2020 Oct 15:1-4. doi: 10.1080/10428194.2020.1834097.

  268. LIU W, Wu M, Xie Y, Zhang C, et al
    Autologous hematopoietic stem cell transplantation with inadequate stem cell dose in patients with non-Hodgkin lymphoma.
    Leuk Lymphoma. 2020 Oct 15:1-7. doi: 10.1080/10428194.2020.1834092.
    PubMed     Abstract available

  269. CUI L, Gao C, Wang CJ, Zhao XX, et al
    Combined analysis of IKZF1 deletions and CRLF2 expression on prognostic impact in pediatric B-cell precursor acute lymphoblastic leukemia.
    Leuk Lymphoma. 2020 Oct 15:1-9. doi: 10.1080/10428194.2020.1832668.
    PubMed     Abstract available

  270. POPHALI PA, Larson MC, Rosenthal AC, Robinson D, et al
    The association of health behaviors with quality of life in lymphoma survivors.
    Leuk Lymphoma. 2020 Oct 13:1-10. doi: 10.1080/10428194.2020.1830389.
    PubMed     Abstract available

  271. RUSSLER-GERMAIN DA, Watkins MP, Bartlett NL
    A forgotten friend: CCNU as palliative monotherapy in relapsed Hodgkin lymphoma.
    Leuk Lymphoma. 2020 Oct 8:1-3. doi: 10.1080/10428194.2020.1830391.

  272. BHURANI M, Admojo L, Van Der Weyden C, Twigger R, et al
    Pralatrexate in relapsed/refractory T-cell lymphoma: a retrospective multicenter study.
    Leuk Lymphoma. 2020 Oct 7:1-7. doi: 10.1080/10428194.2020.1827241.
    PubMed     Abstract available

  273. ALMASMOUM HA, Airhihen B, Seedhouse C, Winkler GS, et al
    Frequent loss of BTG1 activity and impaired interactions with the Caf1 subunit of the Ccr4-Not deadenylase in non-Hodgkin lymphoma.
    Leuk Lymphoma. 2020 Oct 6:1-10. doi: 10.1080/10428194.2020.1827243.
    PubMed     Abstract available

  274. HWANG SR, Higgins A, Castillo Almeida NE, LaPlant B, et al
    Effect of antibiotic use on outcomes in patients with Hodgkin lymphoma treated with immune checkpoint inhibitors.
    Leuk Lymphoma. 2020 Oct 6:1-5. doi: 10.1080/10428194.2020.1827250.

    September 2020
  275. SEGMAN Y, Ribakovsky E, Avigdor A, Goldhecht Y, et al
    Outcome of relapsed/refractory diffuse large B-cell lymphoma patients treated with polatuzumab vedotin-based therapy: real-life experience.
    Leuk Lymphoma. 2020 Sep 27:1-7. doi: 10.1080/10428194.2020.1824069.
    PubMed     Abstract available

  276. TATARCZUCH M, Paul E, Gilberston M, Gregory GP, et al
    Excellent outcomes in older patients with primary CNS lymphoma treated with R-MPV/cytarabine without whole brain radiotherapy or autologous stem cell transplantation therapy.
    Leuk Lymphoma. 2020 Sep 27:1-6. doi: 10.1080/10428194.2020.1821007.
    PubMed     Abstract available

  277. HABERMANN TM, Khurana A, Lentz R, Schmitz JJ, et al
    Analysis and impact of a multidisciplinary lymphoma virtual tumor board.
    Leuk Lymphoma. 2020 Sep 23:1-9. doi: 10.1080/10428194.2020.1817432.
    PubMed     Abstract available

  278. CHANG C, Chen YP, Medeiros LJ, Chen TY, et al
    Higher infiltration of intratumoral CD25+FOXP3+ lymphocytes correlates with a favorable prognosis in patients with diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2020 Sep 23:1-10. doi: 10.1080/10428194.2020.1817438.
    PubMed     Abstract available

  279. KAYA EA, Baughn LB, Pham T, Ketterling RP, et al
    Lymphoma-like double-hit genetic abnormalities (MYC/IGH and IGH/BCL2) in a case of non-secretory multiple myeloma.
    Leuk Lymphoma. 2020 Sep 21:1-4. doi: 10.1080/10428194.2020.1821012.

  280. MOZAS P, Rivero A, Rivas-Delgado A, Nadeu F, et al
    A low lymphocyte-to-monocyte ratio is an independent predictor of poorer survival and higher risk of histological transformation in follicular lymphoma.
    Leuk Lymphoma. 2020 Sep 19:1-8. doi: 10.1080/10428194.2020.1821010.
    PubMed     Abstract available

  281. WALBURN T, Grover NS, Shen CJ, Ranganathan R, et al
    Consolidative or palliative whole brain radiation for secondary CNS diffuse large B-Cell lymphoma.
    Leuk Lymphoma. 2020 Sep 16:1-8. doi: 10.1080/10428194.2020.1821014.
    PubMed     Abstract available

  282. SAMANIEGO F, McLaughlin P, Neelapu SS, Feng L, et al
    Initial report of a phase II study with R-FND followed by ibritumomab tiuxetan radioimmunotherapy and rituximab maintenance in patients with untreated high-risk follicular lymphoma.
    Leuk Lymphoma. 2020 Sep 14:1-10. doi: 10.1080/10428194.2020.1821005.
    PubMed     Abstract available

  283. JAN MRU, Saeed H, Abubakar M, Wali RM, et al
    Response rates, long term outcomes and toxicity profile of gemcitabine and vinorelbine based outpatient chemotherapy regimen in primary progressive and relapsed childhood Hodgkin lymphoma.
    Leuk Lymphoma. 2020 Sep 13:1-9. doi: 10.1080/10428194.2020.1817434.
    PubMed     Abstract available

  284. KIM M, Hwang HS, Son EM, Cho H, et al
    Clinicopathological and prognostic significance of BCL2, BCL6, MYC, and IRF4 copy number gains and translocations in follicular lymphoma: a study by FISH analysis.
    Leuk Lymphoma. 2020 Sep 13:1-9. doi: 10.1080/10428194.2020.1815017.
    PubMed     Abstract available

  285. ANTEL K, Louw VJ, Maartens G, Oosthuizen J, et al
    Diagnosing lymphoma in the shadow of an epidemic: lessons learned from the diagnostic challenges posed by the dual tuberculosis and HIV epidemics.
    Leuk Lymphoma. 2020 Sep 13:1-5. doi: 10.1080/10428194.2020.1815016.
    PubMed     Abstract available

  286. DI M, Panagiotou OA, Reagan JL, Niroula R, et al
    Adjuvant chemotherapy administration and survival outcomes of lymphoma survivors with common solid tumors: a population-based studydagger.
    Leuk Lymphoma. 2020 Sep 11:1-9. doi: 10.1080/10428194.2020.1817433.
    PubMed     Abstract available

  287. NAKAMURA F, Arai H, Tokita K, Furuichi S, et al
    PECAM is an effective and safe anthracycline-containing third-line regimen for patients with relapsed or refractory non-Hodgkin lymphoma.
    Leuk Lymphoma. 2020 Sep 11:1-4. doi: 10.1080/10428194.2020.1817442.

  288. GLOVER A, Fox CP, McMillan A, Beech A, et al
    A comparison of bendamustine-EAM versus BEAM conditioning for autogolous stem cell transplant in lymphoma.
    Leuk Lymphoma. 2020 Sep 8:1-3. doi: 10.1080/10428194.2020.1811863.

  289. STUBBINS RJ, Mabilangan C, Rojas-Vasquez M, Lai RL, et al
    Classic Hodgkin lymphoma post-transplant lymphoproliferative disorders (PTLD) are often preceded by discordant PTLD subtypes.
    Leuk Lymphoma. 2020 Sep 2:1-12. doi: 10.1080/10428194.2020.1808206.
    PubMed     Abstract available

    August 2020
  290. HARWOOD M, Hodges G, Tan X, Cheah CY, et al
    Characteristics and outcome of patients with relapsed/refractory Hodgkin lymphoma following front-line escalated BEACOPP-based chemotherapy: a report from the Australasian Lymphoma Alliance.
    Leuk Lymphoma. 2020 Aug 28:1-5. doi: 10.1080/10428194.2020.1811273.
    PubMed     Abstract available

  291. CHINEN Y, Tanba K, Takagi R, Uchiyama H, et al
    Second primary malignancy after rituximab-containing immunochemotherapy for diffuse large B cell lymphoma.
    Leuk Lymphoma. 2020 Aug 27:1-9. doi: 10.1080/10428194.2020.1811862.
    PubMed     Abstract available

  292. GHIONE P, Qi S, Imber BS, Seshan V, et al
    Modified SMILE (mSMILE) and intensity-modulated radiotherapy (IMRT) for extranodal NK-T lymphoma nasal type in a single-center population.
    Leuk Lymphoma. 2020 Aug 26:1-11. doi: 10.1080/10428194.2020.1811864.
    PubMed     Abstract available

  293. STRAUS D, Collins G, Walewski J, Zinzani PL, et al
    Primary prophylaxis with G-CSF may improve outcomes in patients with newly diagnosed stage III/IV Hodgkin lymphoma treated with brentuximab vedotin plus chemotherapy.
    Leuk Lymphoma. 2020 Aug 25:1-8. doi: 10.1080/10428194.2020.1791846.
    PubMed     Abstract available

  294. XU-MONETTE ZY, Young KH
    Therapeutic vaccines for aggressive B-cell lymphoma.
    Leuk Lymphoma. 2020 Aug 25:1-14. doi: 10.1080/10428194.2020.1805113.
    PubMed     Abstract available

  295. PATEL KK, Isufi I, Kothari S, Foss F, et al
    Cost-effectiveness of polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2020 Aug 24:1-8. doi: 10.1080/10428194.2020.1808208.
    PubMed     Abstract available

  296. CHEN Y, Luo L, Zheng X, Fu H, et al
    Clinical characteristics and survival of extranodal natural killer/T-cell lymphoma: a single-center 12-year retrospective analysis.
    Leuk Lymphoma. 2020 Aug 21:1-13. doi: 10.1080/10428194.2020.1808207.
    PubMed     Abstract available

  297. KRITTIKARUX S, Wudhikarn K, Tangnuntachai N, Assanasen T, et al
    The influence of programmed cell death ligand 2 (PD-L2) expression on survival outcome and tumor microenvironment in diffuse large B cell lymphoma.
    Leuk Lymphoma. 2020 Aug 21:1-9. doi: 10.1080/10428194.2020.1808209.
    PubMed     Abstract available

  298. BAI B, Gao Y, Wang XX, He HX, et al
    Identifying high-risk patients with natural killer/T-cell lymphoma undergoing autologous stem cell transplantation.
    Leuk Lymphoma. 2020 Aug 20:1-8. doi: 10.1080/10428194.2020.1808203.
    PubMed     Abstract available

  299. WEI C, Zhang W, Zhou D
    Central nervous system involvement at diagnosis in extranodal natural killer/T-cell lymphoma: a single-center study.
    Leuk Lymphoma. 2020 Aug 12:1-3. doi: 10.1080/10428194.2020.1804561.

  300. FRASER GAM, Chanan-Khan A, Demirkan F, Santucci Silva R, et al
    Final 5-year findings from the phase 3 HELIOS study of ibrutinib plus bendamustine and rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Leuk Lymphoma. 2020 Aug 6:1-10. doi: 10.1080/10428194.2020.1795159.
    PubMed     Abstract available

  301. OBIORAH IE, Francischetti IMB, Wang HW, Ahn IE, et al
    Concurrent chronic lymphocytic leukemia/small lymphocytic lymphoma and hairy cell leukemia: clinical, pathologic and molecular features.
    Leuk Lymphoma. 2020 Aug 5:1-11. doi: 10.1080/10428194.2020.1797007.
    PubMed     Abstract available

  302. LOSSOS IS, Reis IM, Rosenblatt JD, Alderuccio JP, et al
    Long-term outcomes of frontline (90)Y-ibritumomab tiuxetan in marginal zone lymphoma.
    Leuk Lymphoma. 2020 Aug 5:1-5. doi: 10.1080/10428194.2020.1802449.

  303. SUNDARAM S, Jizzini M, Lamonica D, Attwood K, et al
    Utility of bone marrow aspirate and biopsy in staging of patients with T-cell lymphoma in the PET-Era - tissue remains the issue.
    Leuk Lymphoma. 2020 Aug 4:1-8. doi: 10.1080/10428194.2020.1798950.
    PubMed     Abstract available

    July 2020
  304. CHERIYALINKAL PARAMBIL B, Narula G, Dhamne C, Roy Moulik N, et al
    Assessment of tumor Epstein-Barr Virus status and its impact on outcomes in intermediate and high-risk childhood classic Hodgkin Lymphoma treated at a tertiary cancer center in India.
    Leuk Lymphoma. 2020 Jul 30:1-9. doi: 10.1080/10428194.2020.1800005.
    PubMed     Abstract available

  305. VAN DER WEYDEN C, Harrop S, Prince HM
    Pralatrexate and angioimmunoblastic T-cell lymphoma: time for a second look?
    Leuk Lymphoma. 2020 Jul 30:1-3. doi: 10.1080/10428194.2020.1795164.

  306. SARKOZY C, Scott DW
    Follicular lymphoma - a better understanding to transform outcomes?
    Leuk Lymphoma. 2020 Jul 30:1-3. doi: 10.1080/10428194.2020.1791857.

  307. GIFFORD G, Stevenson W, Best G
    Combination of the dual PIM/PI3-kinase inhibitor IBL-202 and venetoclax is effective in diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2020 Jul 29:1-12. doi: 10.1080/10428194.2020.1795156.
    PubMed     Abstract available

  308. SAWAS A, Ma H, Kuruvilla J, Lue JK, et al
    Prolonged progression free survival in a subset of responders to the combination of brentuximab vedotin and bendamustine in heavily treated patients with relapsed or refractory Hodgkin lymphoma: updated results from an international multi-center phase
    Leuk Lymphoma. 2020 Jul 28:1-4. doi: 10.1080/10428194.2020.1795161.

  309. MEYNARD L, Galtier J, Favre S, Debus L, et al
    Vinblastine for elderly and frail patients with Hodgkin lymphoma.
    Leuk Lymphoma. 2020 Jul 27:1-4. doi: 10.1080/10428194.2020.1797009.

  310. LU T, Gibiansky L, Li X, Li C, et al
    Exposure-safety and exposure-efficacy analyses of polatuzumab vedotin in patients with relapsed or refractory diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2020 Jul 24:1-10. doi: 10.1080/10428194.2020.1795154.
    PubMed     Abstract available

  311. ALBANO D, Mazzoletti A, Zilioli VR, Muzi C, et al
    Clinical and prognostic role of interim 18F-FDG PET/CT in elderly Hodgkin lymphoma: a dual-center experience.
    Leuk Lymphoma. 2020 Jul 24:1-8. doi: 10.1080/10428194.2020.1797012.
    PubMed     Abstract available

  312. ABE R, Mori T, Tanigawa T, Koda Y, et al
    Clinical characteristics and outcomes of duodenal-type follicular lymphoma.
    Leuk Lymphoma. 2020 Jul 22:1-3. doi: 10.1080/10428194.2020.1795162.

  313. WEI L, Wang L, Cong J, Yang L, et al
    Treatment outcomes and prognostic analysis of elderly patients with extranodal natural killer/T-cell lymphoma, nasal type: a retrospective analysis.
    Leuk Lymphoma. 2020 Jul 20:1-7. doi: 10.1080/10428194.2020.1791848.
    PubMed     Abstract available

  314. KHAN N, Feliciano J, Muller K, He M, et al
    Patient preferences for first-line treatment of classical Hodgkin lymphoma: a US survey and discrete choice experiment.
    Leuk Lymphoma. 2020 Jul 20:1-8. doi: 10.1080/10428194.2020.1783443.
    PubMed     Abstract available

  315. SOUMERAI JD, Ni A, Alperovich A, Batlevi C, et al
    Time from diagnosis to 2nd treatment is a promising surrogate for overall survival in patients with advanced stage follicular lymphoma.
    Leuk Lymphoma. 2020 Jul 15:1-8. doi: 10.1080/10428194.2020.1791850.
    PubMed     Abstract available

  316. DESAI SH, Al-Shbool G, Desale S, Veis J, et al
    Lymphoma survivors have an increased long-term risk of chronic kidney disease.
    Leuk Lymphoma. 2020 Jul 11:1-8. doi: 10.1080/10428194.2020.1786555.
    PubMed     Abstract available

  317. MARTINEZ C, Boumendil A, Romejko-Jarosinska J, Anagnostopoulos A, et al
    Second autologous stem cell transplantation for relapsed/refractory Hodgkin lymphoma after a previous autograft: a study of the lymphoma working party of the EBMT.
    Leuk Lymphoma. 2020 Jul 11:1-8. doi: 10.1080/10428194.2020.1789624.
    PubMed     Abstract available

  318. PARTANEN A, Turunen A, Valtola J, Pyorala M, et al
    Autologous stem cell transplantation in peripheral T-cell lymphoma: better mobilization of blood CD34(+) cells is associated with improved survival.
    Leuk Lymphoma. 2020 Jul 10:1-3. doi: 10.1080/10428194.2020.1789629.

  319. FURQAN F, Watson G, Samaniego F, Fayad LE, et al
    Ibrutinib-based therapy for the treatment of marginal zone lymphoma with central nervous system involvement.
    Leuk Lymphoma. 2020 Jul 10:1-5. doi: 10.1080/10428194.2020.1791849.

    Diffuse large B cell lymphoma: splenectomy as a cure for a spleen-limited disease.
    Leuk Lymphoma. 2020 Jul 9:1-4. doi: 10.1080/10428194.2020.1788018.

  321. ISUFI I, Seropian S, Gowda L, Wilson LD, et al
    Outcomes for allogeneic stem cell transplantation in refractory mycosis fungoides and primary cutaneous gamma Delta T cell lymphomas.
    Leuk Lymphoma. 2020 Jul 9:1-7. doi: 10.1080/10428194.2020.1790555.
    PubMed     Abstract available

  322. VIARDOT A, Hess G, Bargou RC, Morley NJ, et al
    Durability of complete response after blinatumomab therapy for relapsed/refractory diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2020 Jul 7:1-4. doi: 10.1080/10428194.2020.1783442.

  323. CHIN CK, Rodriguez MA, Qing Y, Feng L, et al
    Impact of maintenance rituximab in patients with de novo transformed indolent B cell lymphoma.
    Leuk Lymphoma. 2020 Jul 6:1-5. doi: 10.1080/10428194.2020.1789631.

  324. BARRETO JN, Thompson CA, Wieruszewski PM, Pawlenty AG, et al
    Incidence, clinical presentation, and outcomes of Pneumocystis pneumonia when utilizing Polymerase Chain Reaction-based diagnosis in patients with Hodgkin lymphoma.
    Leuk Lymphoma. 2020 Jul 5:1-8. doi: 10.1080/10428194.2020.1786561.
    PubMed     Abstract available

  325. NEEMAN Y, Perry C, Silverman B, Waintraub N, et al
    Rituximab is not associated with increased risk of second primary malignancies in Israeli patients with diffuse large B cell lymphoma treated with RCHOP regimen.
    Leuk Lymphoma. 2020 Jul 1:1-7. doi: 10.1080/10428194.2020.1779257.
    PubMed     Abstract available

  326. BUTEAU JP, Seymour JF, Hofman MS
    The evolving definition of bulky disease for lymphoma.
    Leuk Lymphoma. 2020;61:1525-1528.

  327. JURCZAK W, Dlugosz-Danecka M
    Rituximab biosimilars in clinical practice.
    Leuk Lymphoma. 2020;61:1523-1524.

    June 2020
  328. GUO R, Xu P, Xu H, Miao Y, et al
    The predictive value of pre-treatment (18)F-FDG PET/CT on treatment outcome in early-stage extranodal natural killer/T-cell lymphoma.
    Leuk Lymphoma. 2020 Jun 23:1-6. doi: 10.1080/10428194.2020.1783446.
    PubMed     Abstract available

  329. WUDHIKARN K, Bunworasate U, Julamanee J, Lekhakula A, et al
    Event-free survival at 12 months is a strong surrogate endpoint for stage 1 diffuse large B cell lymphoma: a report from Nation Wide Registry Thai Lymphoma Study Group.
    Leuk Lymphoma. 2020 Jun 23:1-8. doi: 10.1080/10428194.2020.1780586.
    PubMed     Abstract available

  330. MAHAJAN A, Brunson A, Keegan THM, Rosenberg A, et al
    High incidence of venous thromboembolism and major bleeding in patients with primary CNS lymphoma.
    Leuk Lymphoma. 2020 Jun 23:1-9. doi: 10.1080/10428194.2020.1780584.
    PubMed     Abstract available

  331. ALLEN PB, Switchenko J, Ayers A, Kim E, et al
    Risk of bacteremia in patients with cutaneous T-cell lymphoma (CTCL).
    Leuk Lymphoma. 2020 Jun 19:1-7. doi: 10.1080/10428194.2020.1779259.
    PubMed     Abstract available

  332. COYLE L, Morley NJ, Rambaldi A, Mason KD, et al
    Open-Label, phase 2 study of blinatumomab as second salvage therapy in adults with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.
    Leuk Lymphoma. 2020 Jun 16:1-10. doi: 10.1080/10428194.2020.1759055.
    PubMed     Abstract available

  333. EDNERSSON SB, Stern M, Fagman H, Nilsson-Ehle H, et al
    TBLR1 and CREBBP as potential novel prognostic immunohistochemical biomarkers in diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2020 Jun 16:1-10. doi: 10.1080/10428194.2020.1775216.
    PubMed     Abstract available

  334. LU JP, Wang FX, Wen SP, Liu X, et al
    Haploidentical hematopoietic stem cell transplantation with 'Beijing protocol' in the treatment of T-lymphoblastic lymphoma.
    Leuk Lymphoma. 2020 Jun 16:1-4. doi: 10.1080/10428194.2020.1775205.

  335. ZHU J, Yeoh EM, Maeda Y, Tobinai K, et al
    Efficacy and safety of single-agent pralatrexate for treatment of angioimmunoblastic T-cell lymphoma after failure of first line therapy: a pooled analysis.
    Leuk Lymphoma. 2020 Jun 14:1-8. doi: 10.1080/10428194.2020.1765232.
    PubMed     Abstract available

  336. MATSUDA K, Taisuke J, Miyauchi M, Toyama K, et al
    Primary prophylaxis with pegfilgrastim in patients with newly-diagnosed diffuse large B-cell lymphoma: propensity score and instrumental variable analyses.
    Leuk Lymphoma. 2020 Jun 12:1-7. doi: 10.1080/10428194.2020.1775207.
    PubMed     Abstract available

  337. AGRUSA JE, Kothari VD, Brown AL, Masand PM, et al
    Early evidence of pulmonary dysfunction in survivors of childhood Hodgkin lymphoma.
    Leuk Lymphoma. 2020 Jun 10:1-9. doi: 10.1080/10428194.2020.1772478.
    PubMed     Abstract available

  338. LIU J, Stewart D, Fontaine A, Peters A, et al
    Characteristics and outcomes of patients with relapsed follicular lymphoma following retreatment with second-line rituximab-containing chemotherapy.
    Leuk Lymphoma. 2020 Jun 10:1-5. doi: 10.1080/10428194.2020.1772472.

  339. WANG L, Chen XQ, Xia ZJ
    New tricks for old drugs: combination of rituximab and two nanoparticle-delivered chemotherapy drugs, albumin-bound paclitaxel and pegylated liposomal doxorubicin, in the treatment of relapsed/refractory diffuse large B cell lymphoma.
    Leuk Lymphoma. 2020 Jun 6:1-5. doi: 10.1080/10428194.2020.1775206.

  340. TANG C, Espin-Garcia O, Prica A, Kurkreti V, et al
    Efficacy and safety of stem cell mobilization following gemcitabine, dexamethasone, cisplatin (GDP) salvage chemotherapy in patients with relapsed or refractory lymphoma.
    Leuk Lymphoma. 2020 Jun 1:1-8. doi: 10.1080/10428194.2020.1762882.
    PubMed     Abstract available

  341. TADMOR T, Greenfeld S
    Incidence and diagnosis of Richter transformation: transition from the era of chemoimmunotherapy to novel targeted agents.
    Leuk Lymphoma. 2020;61:1272-1274.

  342. STRATI P, Ahmed MA, Nastoupil LJ, Feng L, et al
    Pretreatment SUVmax may influence the clinical benefit of BR over R-CHOP in patients with previously untreated FL.
    Leuk Lymphoma. 2020;61:1380-1387.
    PubMed     Abstract available

    May 2020
  343. HAYASHIDA M, Maekawa F, Chagi Y, Iioka F, et al
    Combination of multicolor flow cytometry for circulating lymphoma cells and tests for the RHOA(G17V) and IDH2(R172) hot-spot mutations in plasma cell-free DNA as liquid biopsy for the diagnosis of angioimmunoblastic T-cell lymphoma.
    Leuk Lymphoma. 2020 May 30:1-10. doi: 10.1080/10428194.2020.1768382.
    PubMed     Abstract available

  344. WEIL CR, Qian Y, Von Eyben R, Daadi SE, et al
    Long-term outcomes of patients with unfavorable stage I-II classic Hodgkin lymphoma treated with Stanford V chemotherapy and limited field irradiation.
    Leuk Lymphoma. 2020 May 30:1-7. doi: 10.1080/10428194.2020.1768385.
    PubMed     Abstract available

  345. HA CS, LeBlanc M, Schoder H, Pinnix CC, et al
    Potential impact of consolidation radiation therapy for advanced Hodgkin lymphoma: a secondary analysis of SWOG S0816.
    Leuk Lymphoma. 2020 May 26:1-6. doi: 10.1080/10428194.2020.1768388.
    PubMed     Abstract available

  346. ASKLID A, Eketorp Sylvan S, Mattsson A, Winqvist M, et al
    A real-world study of first-line therapy in 280 consecutive Swedish patients >/=80 years with newly diagnosed diffuse large B-cell lymphoma: very elderly (>/=85 years) do well on curative intended therapy.
    Leuk Lymphoma. 2020 May 25:1-9. doi: 10.1080/10428194.2020.1765233.
    PubMed     Abstract available

  347. AGUILAR C, Laberiano C, Beltran B, Diaz C, et al
    Clinicopathologic characteristics and survival of patients with primary effusion lymphoma.
    Leuk Lymphoma. 2020 May 25:1-10. doi: 10.1080/10428194.2020.1762881.
    PubMed     Abstract available

  348. YANG R, Huo Z, Duan Y, Tong W, et al
    SOX11 inhibits tumor proliferation and promotes cell adhesion mediated-drug resistance via a CD43 dependent manner in mantle cell lymphoma.
    Leuk Lymphoma. 2020 May 23:1-14. doi: 10.1080/10428194.2020.1762877.
    PubMed     Abstract available

  349. KNEZ V, Bao L, Carstens B, Liang X, et al
    Analysis of clinicopathological and cytogenetic differences between B-lymphoblastic lymphoma and B-lymphoblastic leukemia in childhood.
    Leuk Lymphoma. 2020 May 19:1-7. doi: 10.1080/10428194.2020.1761970.
    PubMed     Abstract available

  350. PICKARD L, Palladino G, Okosun J
    Follicular lymphoma genomics.
    Leuk Lymphoma. 2020 May 19:1-11. doi: 10.1080/10428194.2020.1762883.
    PubMed     Abstract available

  351. MARCHESI F, Capria S, Pedata M, Terrenato I, et al
    BEAM conditioning regimen ensures better progression-free survival compared with TEAM but not with FEAM in lymphoma patients undergoing autologous stem cell transplant.
    Leuk Lymphoma. 2020 May 18:1-4. doi: 10.1080/10428194.2020.1765238.

  352. LANAMTIENG T, Teawtrakul N, Ungarreevittaya P
    Prevalence and clinical characteristics of EBV-positive diffuse large B-cell lymphoma in adult patients: a single center study in Thailand.
    Leuk Lymphoma. 2020 May 14:1-3. doi: 10.1080/10428194.2020.1765240.

  353. GAO C, Harrop S, Van Der Weyden C, McCormack C, et al
    Primary cutaneous anaplastic large cell lymphoma and evolving clinical practice: 26 years of skin lesions with locoregional progression to systemic disease.
    Leuk Lymphoma. 2020 May 12:1-3. doi: 10.1080/10428194.2020.1761972.

  354. FUSEYA H, Yoshida M, Oyama R, Tatsumi N, et al
    Mantle cell lymphoma with dot-like nuclear staining for cyclin D1.
    Leuk Lymphoma. 2020 May 12:1-4. doi: 10.1080/10428194.2020.1759050.

  355. NOZAKI K, Sugahara H, Ueda S, Ishikawa J, et al
    Pretreatment serum soluble interleukin-2 receptor level predicts survival in patients with newly diagnosed follicular lymphoma.
    Leuk Lymphoma. 2020 May 4:1-9. doi: 10.1080/10428194.2020.1759054.
    PubMed     Abstract available

  356. GILE J, Ruan G, Abeykoon J, McMahon MM, et al
    Hypomagnesemia is associated with an increased risk of early clinical failure in patients with Burkitt lymphoma.
    Leuk Lymphoma. 2020 May 2:1-3. doi: 10.1080/10428194.2020.1759056.

    The justification of vincristine dose capping: tradition, tradition...tradition!
    Leuk Lymphoma. 2020;61:1007-1009.

    April 2020
  358. KIM YE, Kim H, Shin J, Min SY, et al
    Stage IV natural killer/T-cell lymphoma with chronic active Epstein-Barr virus, treated with pembrolizumab and TCRalphabeta-depleted haploidentical hematopoietic stem cell transplantation.
    Leuk Lymphoma. 2020 Apr 30:1-4. doi: 10.1080/10428194.2020.1757666.

  359. MERLI M, Defrancesco I, Visco C, Besson C, et al
    Direct-acting antivirals in relapsed or refractory hepatitis C virus-associated diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2020 Apr 28:1-7. doi: 10.1080/10428194.2020.1755859.
    PubMed     Abstract available

  360. RUAN J, Yamshon S, Besien KV, Martin P, et al
    An update on options of therapy for aggressive mantle cell lymphoma.
    Leuk Lymphoma. 2020 Apr 26:1-14. doi: 10.1080/10428194.2020.1755860.
    PubMed     Abstract available

  361. SAWAS A, Ma H, Shustov A, Hsu P, et al
    Characterizing the belinostat response in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma.
    Leuk Lymphoma. 2020 Apr 26:1-5. doi: 10.1080/10428194.2020.1753044.

  362. TERAO T, Narita K, Tsushima T, Miura D, et al
    Mantle cell lymphoma turned SOX11 negative after ibrutinib: a report of two cases.
    Leuk Lymphoma. 2020 Apr 23:1-3. doi: 10.1080/10428194.2020.1742904.

  363. PENG C, Li X, Huang H, Liu T, et al
    A prospective, crossover randomized trial of the optimal timing for leucovorin rescue after high-dose methotrexate management in adult non-Hodgkin's lymphoma patients.
    Leuk Lymphoma. 2020 Apr 22:1-8. doi: 10.1080/10428194.2020.1747061.
    PubMed     Abstract available

  364. LEE K, Ha JY, Jung AR, Lee YS, et al
    The clinical outcomes of rituximab biosimilar CT-P10 (Truxima((R))) with CHOP as first-line treatment for patients with diffuse large B-cell lymphoma: real-world experience.
    Leuk Lymphoma. 2020 Apr 15:1-9. doi: 10.1080/10428194.2020.1742906.
    PubMed     Abstract available

  365. TKACZ J, Garcia J, Gitlin M, McMorrow D, et al
    The economic burden to payers of patients with diffuse large B-cell lymphoma during the treatment period by line of therapy.
    Leuk Lymphoma. 2020 Apr 9:1-9. doi: 10.1080/10428194.2020.1734592.
    PubMed     Abstract available

  366. ZAYAC AS, Olszewski AJ
    Burkitt lymphoma: bridging the gap between advances in molecular biology and therapy.
    Leuk Lymphoma. 2020 Apr 7:1-13. doi: 10.1080/10428194.2020.1747068.
    PubMed     Abstract available

  367. GIFFORD GK, Gifford AJ, Chen Q, Shen Y, et al
    Fatty acid synthase and adenosine monophosphate-activated protein kinase regulate cell survival and drug sensitivity in diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2020 Apr 4:1-13. doi: 10.1080/10428194.2020.1742899.
    PubMed     Abstract available

    March 2020
  368. LIN RJ, Michaud L, Lobaugh SM, Nakajima R, et al
    The geriatric syndrome of sarcopenia impacts allogeneic hematopoietic cell transplantation outcomes in older lymphoma patients.
    Leuk Lymphoma. 2020 Mar 31:1-9. doi: 10.1080/10428194.2020.1742909.
    PubMed     Abstract available

    February 2020
  369. NARAZAKI T, Shiratsuchi M, Matsushima T, Tsuda M, et al
    Clinico-pathological characteristics of primary adrenal lymphomas - potential efficacy of autologous stem cell transplantation.
    Leuk Lymphoma. 2020 Feb 10:1-3. doi: 10.1080/10428194.2020.1725507.

    January 2020
  370. PARIKH SA, Meacham PJ, Zent CS, Evans AG, et al
    Multiple B cell malignancies in patients with chronic lymphocytic leukemia: epidemiology, pathology, and clinical implications.
    Leuk Lymphoma. 2020 Jan 11:1-15. doi: 10.1080/10428194.2019.1709830.
    PubMed     Abstract available

    September 2019
  371. MANCONI L, Coviello E, Canale F, Giannoni L, et al
    Dexamethasone, oxaliplatin and cytarabine (R-DHAOx) as salvage and stem cells mobilizing therapy in relapsed/refractory diffuse large B cell lymphomas.
    Leuk Lymphoma. 2019 Sep 4:1-7. doi: 10.1080/10428194.2019.1658102.
    PubMed     Abstract available

    April 2019
  372. GARCIAZ S, Loschi M, De Masson A, Biard L, et al
    Brentuximab vedotin as a bridge to allogeneic stem-cell transplantation for refractory or relapsing patients with CD30 positive anaplastic or T-cell non-Hodgkin lymphomas: a study on behalf of the SFGM-TC.
    Leuk Lymphoma. 2019 Apr 24:1-4. doi: 10.1080/10428194.2019.1599112.

  373. SHALLIS RM, Gleeson S, Azar M, Malinis M, et al
    Allogeneic stem cell transplantation and combination antiretroviral therapy: cautions, complications, and considerations.
    Leuk Lymphoma. 2019 Apr 3:1-4. doi: 10.1080/10428194.2019.1594221.

Thank you for your interest in scientific medicine.

AMEDEO Malignant Lymphoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.